 
2 Musick • Irvine, CA 92618 • (949) 595-7200 • Fax (949) 595-7373 
www.endologix.com 
Page 1  
 
 
 
 
 
 
CLINICAL STUDY PROTOCOL  
CP-0008 Rev. 11.6 
 
REVISION DATE: APRIL 6, 2018 
  
 
 
Prospective, Multicenter, Single  Arm Safety and Effectiveness 
Study of Endovascular Abdomi nal Aortic Aneurysm Repair 
using the Nellix® System with Continued Access 
 
EVAS I Study with Continued Access 
 
 

Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information cont ained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
2 Table of Contents 
 
Section Page 
1. INVESTIGATOR SIGNATURE PAGE ................................................................................................... ...... 20 
2. STUDY CONTACT PERSONNEL ....................................................................................................... .......... 21 
 SPONSOR  .............................................................................................................................. ................... 21  
 CONTACT NAMES AND TELEPHONE NUMBERS  ...................................................................................... 21  
3. PROTOCOL SYNOPSIS ............................................................................................................. .................... 22  
4. TRIAL OVERVIEW ................................................................................................................ ........................ 26  
4.1. OBJECTIVE  .............................................................................................................................. ................ 26  
4.2. BACKGROUND  .............................................................................................................................. ........... 26 
4.3. STUDY DESIGN  .............................................................................................................................. .......... 28 
5. STUDY POPULATION .............................................................................................................. ..................... 29  
5.1. PRIMARY INVESTIGATION  ...................................................................................................................... 29  
5.2. EXTENDED INVESTIGATION  .................................................................................................................... 30  
5.3. INCLUSION CRITERIA  ............................................................................................................................. 30 
5.4. EXCLUSION CRITERIA  ............................................................................................................................ 3 1 
6. RESPONSE MEASURES ............................................................................................................. ................... 31  
6.1. PRIMARY SAFETY  .............................................................................................................................. ..... 31 
6.2. PRIMARY EFFECTIVENESS  ...................................................................................................................... 32  
6.3. ADDITIONAL EVALUATIONS  ................................................................................................................... 33  
7. STUDY MATERIALS ............................................................................................................... ....................... 34  
7.1. DEVICE DESCRIPTION  ............................................................................................................................ 3 4 
7.2. INVESTIGATOR TRAINING AND EXPERIENCE  ........................................................................................ 37  
7.3. DEVICE ACCOUNTABILITY  ..................................................................................................................... 37  
7.4. PATIENT AND DEVICE PREPARATION  .................................................................................................... 38  
8. STUDY METHODS.................................................................................................................. ........................ 38  
8.1. GENERAL ENTRY PROCEDURES  ............................................................................................................. 38  
8.2. INFORMED CONSENT  ..............................................................................................................................  38 
8.3. SUBJECT IDENTIFICATION  ...................................................................................................................... 39  
8.4. SCHEDULE OF MEASUREMENTS  ............................................................................................................. 39  
8.5. STUDY PROCEDURES AND EVALUATIONS  .............................................................................................. 40  
8.5.1. Informed Consent .............................................................................................................. ........ 40 
8.5.2. CT Scan Protocol .............................................................................................................. ........ 40 
8.5.3. Pre-Operativ e Activ ities ...................................................................................................... ...... 41 
8.5.4. Subject Enro llment ............................................................................................................ ........ 41 
8.5.5. Post-Operative Follo w-up Visits ...............................................................................................  41 
8.5.6. Enhanced Post-Operative Follow-up Visits .............................................................................. 41  
8.6. RECOMMENDED SECONDARY INTERVENTION TREATMENT OPTIONS  ................................................. 42  
8.6.1. Treament Options for Ty pe 1 Endoleaks................................................................................... 42  
8.6.1.1. Type 1A Endoleak s ............................................................................................................. ...... 42 
8.6.1.2. Type 1B Endoleaks ............................................................................................................. ...... 43 
8.6.2. Treatment Options for Migr ation .............................................................................................. 43 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
3 8.6.3. Treatment Options for Aneurysm Expansion ............................................................................ 44  
8.7. PROTOCOL  DEVIATIONS ................................................................................................................ 45  
8.7.1. Deviations with Expedited Reporting Requirements ................................................................ 45  
8.7.2. Deviations Requiring  Prior Approval ........................................................................................ 45  
8.7.3. Non-Urgent Deviations ......................................................................................................... .... 45 
8.8. ADVERSE EVENT REPORTING  ................................................................................................................ 46  
8.8.1. General Definitions ........................................................................................................... ........ 46 
8.8.2. Reporting of A dverse Events ................................................................................................... . 47 
8.8.3. Adverse Events: required reporting tim eframes ........................................................................ 47  
8.8.4. Secondary pr ocedures .......................................................................................................... ..... 47 
8.8.5. Anticipated Adverse Events .................................................................................................... .. 48 
8.8.6. Unanticipated Adverse Device Effect ....................................................................................... 49  
8.8.7. Adverse Event Definitions ..................................................................................................... ... 49 
9. RISK ANALYSIS ................................................................................................................. ............................ 52  
10. STATISTICAL PR OCEDURES ........................................................................................................ ............. 53  
10.1 ANALYSIS POPULATIONS  ........................................................................................................................ 53  
10.2 PATIENT ACCOUNTABILITY AND MISSING DATA .................................................................................. 53  
10.3 GENERAL NOTES  .............................................................................................................................. ...... 54 
10.4 BASELINE COMPARABILITY ANALYSIS  .................................................................................................. 55  
10.5 POOLING  .............................................................................................................................. ................... 55  
10.6 PRIMARY SAFETY ANALYSIS  .................................................................................................................. 56  
10.6.1 PRIMARY SAFETY HYPOTHESIS  ............................................................................................................. 56  
10.6.2 SAMPLE SIZE .............................................................................................................................. ............. 56  
10.6.3 ANALYSIS PLAN .............................................................................................................................. ........ 57 
10.7 PRIMARY EFFECTIVENESS ANALYSIS  .................................................................................................... 58  
10.7.1 PRIMARY EFFECTIVENESS HYPOTHESIS  ............................................................................................... 58  
10.7.2 SAMPLE SIZE .............................................................................................................................. ............. 58  
10.7.3 ANALYSIS PLAN .............................................................................................................................. ........ 59 
10.8 ADDITIONAL EVALUATIONS  ................................................................................................................... 60  
10.9 CONTINUED ACCESS  .............................................................................................................................. . 62 
11. ADMINISTRATIVE PROCEDURES ..................................................................................................... ....... 62 
11.1 STATEMENT OF COMPLIANCE  ................................................................................................................ 62  
11.2 RESPONSIBILITIES  .............................................................................................................................. .... 62 
11.3 PATIENT PROTECTION  ............................................................................................................................ 6 3 
11.4 PROTOCOL CHANGES  ............................................................................................................................. 64 
11.5 DOCUMENTATION  .............................................................................................................................. ..... 64 
11.6 MONITORING PLAN .............................................................................................................................. .. 65 
12. REFERENCES .................................................................................................................... .............................. 67  
13. APPENDIX A: LIST OF COILS INVESTIGATORS MAY USE ADJUNCTIVELY WITH ONYX® ... 68  
 
List of Attachments   
1) Instructions for Use (IFU) 
2) Informed Consent Form (Template) 
 
 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
4 Revision 02 Change Summary 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 01 to version 02, Date 03 July 2012 to 9 Dec 2012. 
Reason: Reflected revision date change in the header. 
Table of 
Contents Updated to reflect revision changes 
1 (4) Updated Investigator Signature page 
Reason: Modified first paragraph to reflect a ccordance with all applicable global laws.  
2.1 (5) 
 Updated General Sponsor Contact 
Reason: to reflect change in Sponsor personnel. 
3 (6) 
5.1 (13) Updated subject population 
Reason: to clarify the number of Roll-in subjects and up to 150 patients in the Intent to Treat Pivotal 
Cohort. 
3 (6) 
7.2 (18) Updated Physician Training 
Reason: The training requirement has been changed to 3 required cases rather than 5 to be cleared 
for study enrollment.  
  4.1 (10) Updated Objective: Added EndoVascular Aneurysm Sealing System 
Reason: To reflect updated product name 
5.2 (13) Inclusion Criteria has been updated: changed d. proximal non-aneurysmal aortic neck; length ≥ 
10mm; lumen diameter 16 to 32mm; angle ≤60° to the aneurysm sac 
added f. Common Iliac artery lumen diameter between 8 and ≤35mm with blood lumen diameter 
with blood lumen diameter ≤35mm g. Ability to preserve at least one hypogastric artery 
Reason: to reflect Anatomic eligibility for the Nellix System per the instructions for use 
6.2 (14) Primary Effectiveness has been updated. Removed defined as migration resulting in serious adverse 
event or requiring secondary intervention through 12 months. 
Revised Secondary endovascular procedure for resolution for endoleak added (type I or type III) Reason: To clarify safety and effectiveness 
6.3 (15) Updated Additional Evaluations. Revised Secondary endovascular procedure within 30 days, at 6 
months, and annually to 5 years for resolution of endoleak Type I and II. 
Reason: to identify the procedure and resolution of endoleak Type I and III 
4.2 (11) Updated Background to include ePTFE covered stent. 
Reason: To reflect the Instructions for Use 
8.6 (23) Updated Protocol Deviation 
Reason: to clearly define a protocol deviation 
8.7.1 (24) Updated Serious Adverse Event Definition 
Reason: For alignment with ISO 14155 definition. 
8.7.3 (26) Added reference to Social Security Death Index (SSD) and CDC National Death Index (NDI) to 
obtain patient death information. 
Reason: Added additional information for sites to acquire patient death information 
(43) Updated monitoring will be performed under the direction of Avi Sharma, Director, Clinical Affairs 
Reason: A new CRO will be contracted. 
Attachment 
2 (2) Revised Informed Consent section 3. Up to 180 patients will be enrolled in the study overall. 
Reason: To reflect the change in the protocol. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
5 Section 
(Page) Change and Reason for the Change 
Attachment 
2 (3) Revised Informed Consent section 4. The US sites will be conducted under an IDE, or Canada under 
an investigational test authorization. 
Attachment 
3  Formatting changed to DD/MMM/YY throughout all Case Report Forms 
Reason: To correct formatting 
Attachment 
3 (1) Revised Screening and Baseline case report form inclusion criteria section 3. Patient aneurysm 
increase of 1.0cm. 
Reason: to reflect the IFU 
Attachment 
3 (1) Revised Screening and Baseline case report form incl usion criteria to include in section 4. Most 
caudal renal artery to aortoiliac bifurcation length ≥ 70 mm 
Reason: to reflect the current IFU 
 
Revision 03 changes 
Note: minor punctuation or formatting ch anges are not included in this table. 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 02 to version 03, Date 09 Dec 2012 to 12 June 2013. 
Reason: Reflected revision date change in the header. 
Table of 
Contents Updated to reflect revision changes 
1 (13) ‘Global’ changed to ‘regional’ 
Reason: PIs follow regional regulations.  Prot ocol requirements will specify any non-regional 
requirements. 
2 (21) CEC and DSMB Name and Address added (Syntactx) 
Reason: CRO is now under contract with Endologix. 
3 (22) Regions of study populations added 
Reason: Clarification of enrollment sites by region. 
3 (22) 3 (25) 
 Site enrollment maximum set to 10% 
Reason: To ensure a more equitabl e enrollment profile across sites 
3(23) 
7.2 (37) Training section – changed from 3 roll-in pe r site to 1 roll-in.  Grammatical changes. 
Reason: Reflect correct roll-in po pulation as specified in Subject Population (page 10) and other 
sections.   
3 (23) 
5.3 (31) Exclusion Criteria #3: Removed words ‘enrollment or 30 day follow-up phase of’ 
Reason: Subjects should not be involved in a competing study at any time frame, as the study 
population should be examining only the Nellix system as a treatment.  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
6 Section 
(Page) Change and Reason for the Change 
3 (24) 
6.2 (32) Primary Effectiveness Endpoint: “E ndoleak type I > 30 days, and Endoleak III” changed to 
“Endoleak type I or Endoleak type III at 12 months ” and additionally  “Secondary endovascular 
procedure up to 12 months for resolution of Endoleak (Type I or Type III)” was added. 
 Reason: The existence of an endoleak is, by itsel f, not necessarily an indication of a clinically 
significant leakage.  Clinically, a failure of effectiveness related to endoleaks would be indicated by a 
re-intervention to re-exclude the aneurysm, or the existence of an endoleak sufficient to cause the 
aneurysm to expand.  Both of those occurrences are considered failures by this endpoint.  Type I or 
III Endoleaks at 12 months (regardless of interven tion or effect) is included to conservatively allow 
for possible future corrective actions. 
 
3 (24) 
3(18) 
10.8 (60) Primary Effectiveness Endpoint: Added in ‘device occlusion’, and ‘may be due to thrombus or other 
causes) to list of secondary procedure causes.   
Reason: Clarity, as requested by FDA (question 44a) 
3 (24) Primary Effectiveness Endpo int: Re-arrangement of metrics. 
Reason: Clarity (most of the metrics refer to sec ondary interventions for va rious device issues; these 
were compiled into a list). 
3 (24) Additional Evaluations: MAE Individual Components: Changed ‘years 1 through 5’ to ‘annually to 5 
years’ 
Reason: Clarity (to match other metric descriptions in this section).  
3 (24) Additional Evaluations: Composite Major Adverse Events: added ’30 days’ to time frames of 
analysis. 
Reason: Error - should have been included (as in the other metrics in this section). 
3 (24) 
4.3 (28) 
6.3 (33) 
8.4 (39) 
10.8 (60) Additional Evaluations: Distal Blood Flow (ABI):  Removed 
Reason: Per the recommendation of the study P.I., ABI (ankle brachial index) is a poor indicator of 
device performance.  Due to the co-morbidities associated with this study population (peripheral 
artery disease), ABI can be permanently elevated in  patients with calcified arteries, rendering ABI a 
poor tool for identifying future changes in blood flow.  Peripheral blood flow, should of course, be examined as per physician standard of care. 
J Am Coll Cardiol.  2008 Apr 1;51(13):1292-8. doi: 10.1016/j.jacc.2007.11.064. 
doi: 10.2337/di acare.26.12.3333 Diabetes Care December 2003 vol. 26 no. 12 3333-3341  
3 (24) 
6.3 (33) 
8.7.7 (46) 
10.8 (60) Additional Evaluations: Luminal Thrombus Requiring  Intervention at each st udy timepoint: Metric 
and definition added 
Reason: Response to FDA’s request concerning thrombus formation (question 46), thrombus has also 
been added as a separate metric for evaluation (in addition to being part of the effectiveness endpoint). 
3 (25) Statistical Considerations: Study Population: 1st paragraph changes 
Reason: Clarity to Intent to treat population definition, and to enrolled status. 
3 (25) Statistical Considerations: Study Population: Per Protocol population paragraph added. 
Reason: Clarify the Per Protocol population definition. 
3 (25) Statistical Considerations: Study Population: Completed Cases paragraph added. 
Reason: Clarify the Completed Cases population definition. 
7 (34) Study Materials: Single use or multiple use added to each component. 
Reason: Clarity (and Dispenser should have been specified multiple use). 
  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
7 Section 
(Page) Change and Reason for the Change 
7.2 (37) Investigator Training item #2: added word ‘approximately’ to case number requirement 
Reason: Sub-investigator qualifications for implan tation with regard to prior EVAR experience will 
be done on a case-by-case basis; however, 25 cases will be treated as a rough baseline. 
7.3 (37) Device accountability: added in ‘prior to implantation’ 
Reason: Clarity.  Return of all device components can only occur if the device was not implanted. 
8.1 (38) 
11.2 (49) Addition of ‘independent physician review. 
Reason: Addition of more detail regarding patient approval process. 
8.2 (38) ‘global standards’ changed to ‘Good Clinical Practices’ 
Reason: Clarity 
8.3 (27) Changed title of Section 8.3 to properly reflect subsequent content 
Reason: Error, and as noted in FDA question #49. 
8.3 (27) Removal of methodology for patient naming. 
Reason: Patient IDs will be automatical ly generated within the eDC system. 
8.5.4 (40) Addition of sentence “If, during the index pr ocedure, the device is not implanted and/or there is 
conversion to open surgery, the patient will be followed until the 30 day follow-up” 
Reason: Clarification of fo llow-up process for patients that either  do not receive the study device, or 
are converted to open surgery. 
8.7.1 (46) ‘…administered a product…’ changed to ‘…enrolled in the trial…’ 
Reason: Correction.  AE reporting also applies to subjects who did not receive the product, but were 
enrolled. 
8.7.2 (46) 
8.7.3 (46) Sections rewrite 
Reason: Consolidation.  Many paragraphs in these two sections contained repetitious instructions.  
The adverse event reporting process is roughly the same regardless of the type of adverse event.   
 
AE reporting time requirements (from the site to Endologix), while mentioned, were scattered 
throughout text and difficult to acces s quickly.  A table of “Adver se Events: required reporting 
timeframes” was generated to address this.   
 Requirements for reporting and investigating a subject death were consolidated into one section. 
There were no substantive changes. 
8.7.4 (46) Removal of word ‘endovascular’ from section title 
Reason: Correction.  Procedures discussed also refer to open repair. 
8.7.4 (46) Removal of fax information. 
Reason: reporting in this trial will be electronic via EDC. 
8.7.6 (46) Addition of Endologix reporting timeframes of UADEs.  Removal of fax information 
Reason: Reporting will be done by the EDC system in this trial.  Clarify Endo logix response to such 
an event. 
8.7.7 (46) 
10.8 (60) Revised definition for Clinically Significant Migration: 
Reason: Updated for consistency within the document. 
8.7.7 (46) Removal of definitions of various adverse events 
Reason: Consolidation.  Definitions in the protocol will be limited to endpoints and device specific 
issues.  All other clinical events will be defined by the independent CEC (Syntactx) 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
8 Section 
(Page) Change and Reason for the Change 
8.7.7 (46) Revised Distal Ischemia Definition: Removed”…A  reduction in ABI of 0.15 or more attributable to 
the index procedure and not related to natural progression of atherosclerotic disease is included in this 
definition. 
Reason: See change #17 
8.7.7 (46) 
10.8 (60) Revised Migration definition: 
Reason: Defined per migration from the renal artery and removed intervention criteria to include all 
device migrations >5 mm. 
8.7.7 (46) Addition of device occlusion to secondary procedures. 
Reason: Treatment can also be open surgery.  Obstruction and occlusion will cover any thrombus 
related events (FDA Question 44). 
8.7.7 (46) Removal of word  ‘endovascular’ from Seconda ry Procedure definition  
Reason: See change#47 
10.1 (53) Removal of ‘with imputation for missing data…” 
Reason: Removed for redundancy as this is explained in the next section.  
10.1 (53) Addition of ‘or have expired prior to 12 months’ 
Reason: Per FDA request (Question 47), provide further clarification on the Completed Cases 
analysis population. 
10.1 (53) Completed case (CC) changes; removal of one sentence, addition of another 
Reason: Clarity.   
10.2 (53) Addition ‘prior to procedure’ 
Reason: Clarity (this listing is for patients who never officially enrolled) 
10.2 (53) Change of ’15 subj ects’ to ‘10% of study enrollment’ (2 places in paragraph) 
Reason: Quantify the amount of total enrollment a given clinical site can contribute to the study. 
10.2 (53) Removal of sentence “In the control group, no subjects were…” 
Reason: Per FDA request (Question 51), there will be  no control group comparator for this study. 
10.2 (53) Addition of paragraph beginning with “In addition to the above…” 
Reason: Per FDA request (Question 52), Tipping Point Analyses has been included. 
10.5 (55) Addition of sentence beginning “The estimates obtained…” 
Reason: Per FDA request (Question 53), provided add itional clarification pertaining to heterogeneity 
of study sites. 
10.6 (56) For entire section: removal of word ‘control’. 
Reason: Clarity.  SVS open surgery group provides a historical OPC for this trial.  The SVS group is 
not a direct control (i.e., patient level data) in this trial.  
10.6 (41) For entire section: change ‘test group’ to ‘study population’ 
Reason: Clarity.  ‘Test group’ normally refers to one arm of a two arm trial.  This trial is not designed 
as a two arm trial. 
10.6.2 (56) Changes to sentence beginning with ‘The sample size of this trial…” 
Reason: Clarity.  ‘Test group’ normally refers to one arm of a two arm trial.  This trial is not designed 
as a two arm trial. 
10.7.1 (58) Addition of sentence beginnin g with “The hypothesis test will be…” 
Reason:  Clarification of the significance le vel and for consistency within the document. 
10.7.2 (58) Revision of endpoint description 
Reason: Updated to reflect endpoint changes. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
9 Section 
(Page) Change and Reason for the Change 
11.2.5 (48) Added “An independent clinical safety review w ill examine all AEs and SAEs.  MAEs will undergo 
adjudication by the CEC panel.” 
Reason: Events that the CEC will review were  clarified per FDA IDE response question #11. 
11.5 (64) Revised Study log maintenance description 
Reason: Updated to reflect current pr actices for study log maintenance.  
Attachment 
2 (2) Added prior clinical studies in formation to informed consent 
Reason: This change was implemented per a request in FDA IDE Response question #13. 
Attachment 
2 (4)  Added information pertaining to follow-up of enrolled patients where the study device is not 
successfully implanted during th e index procedure or patients wh ere the device is explanted. 
Reason: Protocol CP-0008 Rev.03 was updated with a 30-day follow-up period for patients where the 
device is not successfully implanted, if the patient is converted to open surgery, or if the device is 
explanted with open surgical repair. 
Attachment 
2 (9) Added US Clinical Trials.gov publishing requirement  
Reason: To inform patients that information on this study will be available on the internet. 
Attachment 
3 (All) Paper CRFs were converted to electronic CRFs 
Attachment 
3 (5) Revised from: “Most caudal renal artery to aorto-iliac bifurcation length >= 70 mm”.  To: “ Most 
caudal renal artery to each hypogastric artery length 100mm” 
Reason: Updated to reflect current inclusion exclusion criteria per discrepancy noted in FDA IDE 
response question #14. 
Attachment 
3 (5) Revised from: “Is there clinically significant in frarenal mural thrombus (>5mm thick over >60% 
circumference)” To:…(>5 mm thick over >50% circumference)  
Reason: Updated to reflect current inclusion exclusion criteria per discrepancy noted in FDA IDE 
response question #14.  
Attachment 
3 (17) Removed: Nellix Extenders were removed from the CRFs 
Reason: Extenders are not planned to be used in this clinical study. This addresses FDA IDE response 
question #12 
 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
10 
 
 
 Revision 04 changes 
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 03 to version 04, Date 12 June 2013 to May 2014. 
Reason: Reflected revision date change in the header. 
2 (13) Added “…with conditions of the approval impos ed by the reviewing Ethics Committee or Institutional 
Review Board….I agree to maintain adequate source documentation records throughout the clinical 
investigation and make them available as requested during monitioring visits. I agree to maintain the device accountability records and ensure that the inve stigational device is used solely by authorized 
users as specified by this protocol.  
 I agree to ensure that the requirements for obtaining informed consent are met.  
 
Additionally, I agree to disclose financial interests in accordance with 21 CFR 54, and certify that such 
financial interests, if any, will not interfere with my  responsibilities as an investigator or influence study 
outcomes under my supervision.  
 Reason: These statements were added to the investigat or signature page to centralize requirements from 
21 CFR 812.43 (C) and ISO 14155 that were reflected across several study agreements.  
3 (15) Removal of Canada from the list of countries 
 Reason: Canada no longer has active sites in this trial.  No patients were enrolled at either site. 
3 (15) Change the site maximu m enrollment from 10% to 15%. 
 
Reason: For consistency with prior EVAR trials. 
3 (16) Revised Inclusion criteria #4 for the maximum abdominal aortic aneurysm (AAA) sac diameter size 
from: “≥5.5cm or ≥4.5 cm which has increased by >1.0 cm within the last year” to:  “ ≥5.0cm, or ≥4.5 
cm which has increased by ≥0.5cm within the last 6 months, or which exceeds 1.5 times the 
transverse dimension of an adjacen t non-aneurysmal aortic segment”. 
 
Reason: As recommended by the trial Physicia n Steering Committee, for alignment with SVS 
practice guideline recommendations and aneurysm  dimensional inclusion criteria among most 
recently approved products/labelin g, including Medtronic Endurant , Trivascular Ovation, Lombard 
Anaconda, and Endologix (PEVAR). 
3 (16) Revised Exclusion criteria#10 of section #3 of clinically significant mural thrombus from” Clinically 
significant infrarenal mural thrombus (>5mm thic kness over >50% circumference)“ to “Clinically 
significant mural thrombus within the proximal landing zone (minimum 10mm) of the infrarenal non-
aneurysmal neck (>5mm thickne ss over >50% circumference)” 
 
Reason: Clarification of exclusion cr iterion.  This revision clarifies that the mural thrombus exclusion 
applies to the infrarenal  non-aneurysmal neck. 
4.2 (20) Added text beginning with “There are a number of qualifiers…” 
 
Reason: For clarification only. 
5.1 (22) Change the site maximum enrollment from 10% to 15% 
 
Reason: For consistency with prior EVAR trials. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
11 
 
 
 Section 
(Page) Change and Reason for the Change 
5.2(22) Revised Inclusion criteria #4 for the maximum abdominal aortic aneurysm (AAA) sac diameter size 
from: “≥5.5cm or ≥4.5 cm which has increased by >1.0 cm within the last year” to:  “ ≥5.0cm, or ≥4.5 
cm which has increased by ≥0.5cm within the last 6 months, or which exceeds 1.5 times the 
transverse dimension of an adjacen t non-aneurysmal aortic segment”. 
 
Reason: As recommended by the trial Physicia n Steering Committee, for alignment with SVS 
practice guideline recommendations and aneurysm  dimensional inclusion criteria among most 
recently approved products/labelin g, including Medtronic Endurant , Trivascular Ovation, Lombard 
Anaconda, and Endologix (PEVAR). 
5.3 (23) Revised Exclusion criteria #10 of section 5.3 of clinically significant mural thrombus from” 
Clinically significant infrarenal mural thrombus  (>5mm thickness over >50% circumference)“ to 
“Clinically significant mural thrombus within the proximal landing zone (minimum 10mm) of the 
infrarenal non-aneurysmal neck (>5mm thickness over >50% circumference)”  
Reason: Clarification of exclusion criterion.   
7.2 (28) Revised review requirement for investigator training from” review of Investigator Brochure” to 
“review of prior clinical safety  and effectiveness information”. 
 
Reason: To reflect actual practice. 
7.2 (28) Added criteria for sub-Investigators who lead the implant procedures “For procedures led by a sub-
investigator, the PI must be present to provide supe rvision of the case, unless the sub-Investigator has 
completed investigational device training and ha s received documented approval by Endologix.” 
 
Reason: Clarification of possible sub-investigator qualifications. So me sub-investigators will receive 
the full PI/proctor training. 
8.3 (30) Added subject number allocation system “Subject numbers will be automatically assigned by the 
EDC system” 
 
Reason: Subject number allocation was inadvertently missed in the previous revision. 
8.3 (30) Clarified screening log maintenance “eith er on paper or electronically in the EDC” 
 Reason: Screening log can be maintained by either method (paper or electronically). 
8.5.2(30) Clarified slice thickness criteria from “<3mm” to “<=3mm” 
 
Reason: Typographical error: CT Scan sli ce thickness equal to 3mm are acceptable.   
8.5.4 (30) Revised subject enrollment section to clarify screen failures. “If the device does not contact the 
patient, the patient will not be considered enrolled and the assigned study number will not be given to 
another patient and the patient is considered as a screen failure” 
 Reason:  Further clarified screen failures and patient numbers assignment in screen failures. 
8.5.4 (31) Revised conditions, when device is not implanted during index procedure. “If, during the index 
procedure, the device is introduced but is not implanted and/or there is conversion to open surgery, 
the patient will be followed until the 30 day follow-up.”  
Reason:  Further clarified situation when devices are not implanted during index procedure. 
8.5.5 (32) Removed site reference manual from instruction to complete, from “site reference manual” to “site 
initiation visit”. 
Reason: The site personnel are trained during site initiation visit on how to enter data into eCRFs. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
12 
 
 
 Section 
(Page) Change and Reason for the Change 
8.7.2 (35) Added “If approval is obtained from the patient or a patient’s authorized family member, the site 
should notify Endologix of the explant”. 
 
Reason: Added requirement to include patient’s authorization and to notify the sponsor once obtained. 
8.7.7 (36) Pulmonary related death was moved from page 35 
 Reason: Pulmonary related death was located in the wrong section. 
8.7.7(36) Removed definition for Migration from “death” section to “other definitions ” section 
 
Reason: Editorial correction only. 
8.7.7 (37) Added “…and is still present at the 30 day CT  as read by the Core Lab”  to Procedural Technical 
Failure definition. 
 
Reason: Clarify definition of unresolved endoleak. 
10.2 (41) Removed “…and imputing the mean from all subjects with outcomes.” 
 
Reason: Including this additional method is not rele vant since the endpoint is  dichotomous and not a 
continuous variable from which a mean can be calculated across patients.  
10.5 (42) Replaced Logisitic Regressi on using a univariate model of st udy site with … “extension of the 
Fisher’s exact test (Fisher-Freeman-Halton).” 
 
Reason: This replacement is better suited for testing homogeneity across study sites.  
10.5 (42)  Added “Both the safety an d effectivness measures will employ weighted proportions as the basis for 
the statistical test.”  
 
Reason: Changed for clarity, as the approach to weighing estimates of the proportions as described by 
the Method of Fleiss (1993) is the same for all endpoints. 
10.6 (43) Changed: “… greater…” to “…less…” 
 Reason: This was a typographical er ror. The sentence was updated to re flect actual statistical test that 
shows significant heterogeneity when the p-value is less than 0.15.  
10.6 (43) Removed “Secondary Procedures” from the primary safety hypothesis  
 Reason: This was inadvertently added to the primar y safety hypothesis as secondary procedures are 
represented in the primary effectiveness analysis.  
10.6.3 (44) Updated equation:  
1
11



k k
kk p pnW  
Reason: There was a typographical error in the previous version of this equation. This equation was 
intended to show that weight is equal to the inverse of the variance. 
ICF (3) Study Questions, #3: Changed to ‘enroll up to 31 patients’ 
 
Reason: to match up to maximum site enrollment 
ICF (4) Blood Pressure : removed descriptive text ‘… measured at your arms and ankles’ 
 
Reason: protocol only specifies a normal blood pressure exam. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
13 
 
 
 Section 
(Page) Change and Reason for the Change 
ICF (10) Change “Endologix fenestrate d device” to “Nellix system” 
 
Reason : Incorrect system title. 
 
Revision 05 changes 
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 04 to version 05, Date Jun 2014 to Nov 2014. 
Reason: Reflected revision date change in the header. 
Table of 
Contents Updated to reflect revision changes 
3 (16) Updated protocol title, both short and long, to re flect the addition of Conti nued Access (as a separate 
cohort) 
3 (16) Clarified ‘Study Devices’ to include full name of device 
3 (18) Enrollment section changed to clarify the tw o trial phases: the Primary Investigation, and the 
Extended Investigation (Continued Access). Added the expected Extended Investigation enrollment 
and closure timeframe. 
5.1 (23) Changed title of section to ‘Primary Investigation’ for clarity. 
5.2 (23) New section added to explain details of the Extended Investigation.  The section elucidates 1) the 
expected enrollment, 2) th e expected time of enrollment, and 3) the sites that invited to participate. 
8.7.2 (36) Updated company clinical fax number 
10.9 (49) New section added to explain statistical treatment of the Continued Access cohort. 
  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
14 
 
 
 Revision 06 changes 
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 05 to version 06, Date Nov 2014 to Feb 2015. 
Reason: Reflected revision date change in the header. 
Table of 
Contents Updated to reflect revision changes 
3 (17) Updated Continued A ccess population size to 100 
Reason: Reflected total popula tion size for Continued Access 
5 (24) Updated Continued A ccess population size to 100 
Reason: Reflected total popula tion size for Continued Access 
 
Revision 07 changes 
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
Title Page Updated company address 
Reason: 2 Musick, Irvine, CA 92618 is location of new headquarters 
All Pages Changed all pages to protocol version from 06 to version 07, Date Feb 2015 to Apr 2015. 
Reason: Reflected revision date change in the header. 
Table of 
Contents Updated to reflect revision changes 
2 (16) Updated company address 
Reason: 2 Musick, Irvine, CA 92618 is location of new headquarters 
3 (18) Updated minimum proximal non-anuerysmal aortic neck lumen diameter from 16mm to 18mm and 
the minimum common iliac artery lu men diameter from 8mm to 9mm 
Reason: Corresponds with updated IFU.  The original anatomical parameters in both the IFU and the 
earlier protocol versions allowed for the possible use of 8mm Nellix stent diameters. The Core Lab 
has already been using these more restrictive parameters to determine eligibility throughout the trial, 
as Nellix 8mm stents were never utilized or implanted during the study. 
5 (25) Updated minimum proximal non-anuerysmal aortic neck lumen diameter from 16mm to 18mm and 
the minimum common iliac artery lu men diameter from 8mm to 9mm 
Reason: Corresponds with updated IFU.  The original anatomical parameters in both the IFU and the 
earlier protocol versions allowed for the possible use of 8mm Nellix stent diameters. The Core Lab 
has already been using these more restrictive parameters to determine eligibility throughout the trial, as Nellix 8mm stents were never utilized or implanted during the study. 
11 (54) Updated company address 
Reason: 2 Musick, Irvine, CA 92618 is location of new headquarters 
  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
15 
 
 
  
Revision 08 changes (VER SION WAS NOT RELEASED) 
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 07 to version 08, Date May 2015 to Aug 2015. 
Reason: Reflected revision date change in the header. 
3 (17) Updated Continued A ccess population size to 270 
Reason: Reflected total popula tion size for Continued Access 
5 (24) Updated Continued A ccess population size to 270 
Reason: Reflected total popula tion size for Continued Access 
 
Revision 08.1 changes 
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 08 to version 08.1, Date May 2015 to October 2015 
Reason: Reflected revision date change in the header. 
3 (18) Updated Continued A ccess population size to 150 
Reason: Reflected total popula tion size for Continued Access 
5 (25) Updated Continued A ccess population size to 150 
Reason: Reflected total popula tion size for Continued Access 
 
Revision 09 changes 
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 08.1 to version 09, Date October 2015 to April 2016 
Reason: Reflected revision date change in the header. 
3 (18) Updated Continued A ccess population size to 250 
Reason: Reflected total popula tion size for Continued Access 
5 (25) Updated Continued A ccess population size to 250 
Reason: Reflected total popula tion size for Continued Access 
 
Revision 10 changes (VER SION WAS NOT RELEASED) 
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 09 to version 10, Date April 2016 to June 2016 
Reason: Reflected revision date change in the header. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
16 
 
 
 Section 
(Page) Change and Reason for the Change 
2.1 (18) Changed sponsor contact 
Reason: Updated based on current organizational structure.  
3 (20) Changed anatomical inclusion criteria of blood lumen diameter from ≤ 60 mm to ≤ 70 mm 
Reason: Expanded treatable blood lumen diamet ers in updated Instructions for Use (IFU). 
5 (27) Changed anatomical inclusion criteria of blood lumen diameter from ≤ 60 mm to ≤ 70 mm 
Reason: Expanded treatable blood lumen diamet ers in updated Instructions for Use (IFU). 
7 (30) Changed dispenser from multiple use to single use 
Reason: Disposable dispensers are now available to use.  
7.1 (30) Replaced "polyurethane bag (EndoBag) having a polyester reinfo rcement sleeve" with polyurethane 
EndoBag with welded seams and a lumen having an inner polyester (PET) sleeve is attached to the 
stent proximally and distally using polyethylene sutures 
Reason: Describes the changes to the the EndoBag, with  the distal end now also attached to the stent. 
7.1 (31) Updated the name of the pressure monitor from Mirador Compass™ to Centurion™ Biomedical 
Compass™ 
Reason: Mirador Biomedical is now a subsidiary of Centurion Medical Products, Inc. 
7.1 (32) Replaced the pi cture of the console 
Reason: Console was updated from 4 ports to 3. 
8.7 (40) Added sentence: “These events must be reported if clinically significant.” 
Reason: To emphasize the impo rtance of reporting any clinically significant AE. 
11.6 (57) Changed sponsor contact 
Reason: Updated based on current organizational structure.  
 
 
Revision 10.1 changes 
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 09 to version 10.1, Date April 2016 to September 2016 
Reason: Reflected revision date change in the header. 
2.1 (18) Changed sponsor contact 
Reason: Updated based on current organizational structure.  
7 (30) Changed dispenser from multiple use to single use 
Reason: Disposable dispensers are now available to use.  
7.1 (30) Replaced "polyurethane bag (EndoBag) having a polyester reinfo rcement sleeve" with polyurethane 
EndoBag with welded seams and a lumen having an inner polyester (PET) sleeve is attached to the 
stent proximally and distally using polyethylene sutures 
Reason: Describes the changes to the the EndoBag, with  the distal end now also attached to the stent. 
7.1 (31) Updated the name of the pressure monitor from Mirador Compass™ to Centurion™ Biomedical 
Compass™ 
Reason: Mirador Biomedical is now a subsidiary of Centurion Medical Products, Inc. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
17 
 
 
 Section 
(Page) Change and Reason for the Change 
7.1 (32) Replaced the pi cture of the console 
Reason: Console was updated from 4 ports to 3. 
8.7 (40) Added sentence: “These events must be reported if clinically significant.” 
Reason: To emphasize the impo rtance of reporting any clinically significant AE. 
11.6 (57) Changed sponsor contact 
Reason: Updated based on current organizational structure.  
 
 
Revision 11.1 changes (VER SION WAS NOT RELEASED) 
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 10.1 to version 11,0 Date September 2016 to May 2017 
Reason: Reflected revision date change in the header. 
3 (21) Updated proximal non-anuerysmal aortic neck lumen diameter from 18mm-32mm to a neck diameter 
of 18mm-28mm and added: Distal iliac artery seal zone with length of ≥10mm, diameter range of 9 
to 25mm and ratio of maximum aortic aneurysm di ameter to maximum aortic  blood lumen diameter 
<1.40.   
Reason: Corresponds with  updated IFU.    
5 (28) Updated proximal non-anuerysmal aortic neck lumen diameter from 18mm-32mm to a neck diameter 
of 18mm-28mm and added: Distal iliac artery seal zone with length of ≥10mm, diameter range of 9 
to 25mm and ratio of maximum aortic aneurysm di ameter to maximum aortic  blood lumen diameter 
<1.40.   
Reason: Corresponds with  updated IFU.    
8.4 (37) Updated table to reflect enhanced follow-up visits 
Reason: Schedule of Measurements summarize assessm ents at each timepoint in  the study, including 
enhanced follow-up.  Added footnote to table to clarify population affected by the new follow-up 
recommendations. 
8.5.6 (38) Added section for enhanced post-operative follow-up visit. 
Reason: Enhanced follow-ups ar e recommended to monitor at-risk for migration, Type 1A 
endoleaks and/or AAA sac enlargement. 
 
 
Revision 11.2 changes (VER SION WAS NOT RELEASED) 
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 11.1 to version 11,2 Date June 2017 to July 
Reason: Reflected revision date change in the header. 
8.6 (38) Added section of recommended secondary intervention treatment options. 
Reason: Provides options to Nellix Investigators to treat subjects who experience migration, Type 
1A endoleaks and/or AAA sac enlargement. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
18 
 
 
  
Revision 11.3 changes  
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 11.2 to version 11.3 Date July 2017 to August 
Reason: Reflected revision date change in the header. 
8.6.1 (40) Updated table to reflected recommended secondary intervention treatment options for Type 1A 
Endoleaks Reason: When positioned correctly, with adequate seal, Onyx® can be used to treat Type 1A 
endoleaks. 
Appendix Added appendix of coils to be used with the Onyx Liquid Embolics System 
Reason: Reflects list of peripheral vascular coils available in the US, that allows physican to use 
preferred standard coil.  
 
Revision 11.4 changes (VER SION WAS NOT RELEASED) 
Note: minor punctuation or formatting ch anges are not included in this table. 
 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 11.3 to version 11.4 Date March, 2018.   
Reason: Reflected revision date change in the header. 
2.1 (20)  Updated general sponsor contact  
Reason: Updated based on current organizational structure  
4.3 (23) Added enhanced follow-up reference 
Reason: To ensure that all types of visits are being addressed 
8.5.6 (41) Updated definition of an “at risk” subject, and added definition of an “inadequate procedure” 
Reason: New analysis based on current unders tanding of Nellix implantation best practices 
8.6 (42) Included physician training and proctoring for recommended secondary interventions. Also 
included “bailout procedure”, “Secondary ChEVAS”, “NiNA with Polymer, and NiNA without 
Polymer”, as alternative termoniology used. 
Reason: To provide a more clear understanding of secondary intervention treatment options 
 
Revision 11.5 changes (VER SION WAS NOT RELEASED) 
Note: minor punctuation or formatting ch anges are not included in this table. 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 11.4 to version 11.5  Date March, 2018.   
Reason: Reflected revision date change in the header. 
8.5.6 (41) Added punctuation to an inadequate procedure definition. 
Reason: Updated per FDA request 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
19 
 
 
 Revision 11.6 changes  
Note: minor punctuation or formatting ch anges are not included in this table. 
Section 
(Page) Change and Reason for the Change 
All Pages Changed all pages to protocol version from 11.5 to version 11.6 Date April, 2018.   
Reason: Reflected revision date change in the header. 
8.5.6 (39) Added clarification to inadequate procedure definition  
Reason: Updated per FDA request 
  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
20 
 
 
  
1. INVESTIGATOR SIGNATURE PAGE 
 
I agree to conduct the study as detailed in the protoc ol and in accordance with conditions of the approval 
imposed by the reviewing Ethics Committee or Institutiona l Review Board, all applicable regional laws and 
regulations. I agree to maintain adequate source docum entation records throughout the clinical investigation 
and make them available as requested during mon itioring visits. I agree to maintain the device 
accountability records and ensure that the investigationa l device is used solely by authorized users as 
specified by this protocol. In addition, I agree to pr ovide all the information requ ested in the electronic Case 
Report Forms presented to me by the Sponsor in a manner to assure completeness and accuracy.   
I agree to ensure that the requirements for obtaining informed consent are met. I agree to actively enroll 
consecutive subjects into this study and confirm that I am not currently participating in any clinical 
investigations for similar types of medical devices that  would inhibit my ability to participate fully in this 
study. Additionally, I agree to di sclose financial interests in accordan ce with 21 CFR 54, and certify that 
such financial interests, if any, will not interfere with my responsibilities as an investigator or influence 
study outcomes under my supervision.  
I also agree that all information provided to me by th e Sponsor, including pre-clinical data, protocols, Case 
Report Forms, and any verbal and writte n information, will be kept strictly  confidential and confined to the 
clinical personnel involved in conducting the study. It  is recognized that this information may be relayed 
in confidence to the Ethics Committee or Institutional Review Board, or to regulatory authorities.   
In addition, no reports or informa tion about the study or its progress will be provided to an yone not involved 
in the study other than the Sponsor, or its representati ves, the Ethics Committee(s), the Institutional Review 
Board(s), or the core lab. Any such submission will indicate that the material is confidential. 
 
      
 
      
Investigator Signature  Date 
 
 
   
Investigator Printed Name  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information cont ained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
21 
 
 
 2. STUDY CONTACT PERSONNEL 
 SPONSOR  
 
GENERAL SPONSOR CONTACT  
Meredith Huetter 
VP, Clinical Affairs 
Endologix, Inc. 2 Musick 
Irvine, CA 92618 Tel: (949) 598-4650  Fax: (949) 954-7601  
Email:
 mhuetter@endologix.com 
 
 CONTACT NAMES AND TELEPHONE NUMBERS  
CT SCAN CORE LABORATORY  
Cleveland Clinic Peripheral Vascular 
Core Lab 
Contact: Paul Bishop, MSEE, RVT 
3050 Science Park Drive (AC3-24) 
Beachwood, OH 44122 
Tel : (216) 448-0539 Fax : (216) 448-0538 Email : bishopp@ccf.org  
 
INDEPENDENT MEDICAL REVIEWER   CLINICAL EVENTS COMMITTEE & DSMB 
Name on file with Sponsor  Syntactx  
Contact: Kenneth Ouriel, MD, MBA  7 World Trade Center, 46th Floor  
New York, New York 10007 Tel : (212) 266-0135  kouriel@syntactx.com 
 
 
 
  
 
  
 
 
 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
22 
 
 
  
 
3. PROTOCOL SYNOPSIS 
 
Title: Prospective, Multicenter, Single Arm Safety and Effectiveness Study of  
EndoVascular Abdominal Aortic Aneurysm Repair Using the Nellix® System with 
Continued Access 
 
Short Title:           EVAS I Study with Continued Access 
 
Study Devices : Nellix EndoVascular Aneurysm Sealing System (Nellix System) 
 Study Sponsor:  Endologix, Inc. 
 
Objectives : To study the safety and effectiveness of the Nellix System for Endovascular 
Abdominal Aortic Aneurysm (AAA) repair . Procedures will be performed per the 
instructions for use, and per institutional protocols and standard of care for endovascular aneurysm repair. As such, th is study will evaluate the safety and 
effectiveness of the device system among a wide range of physicians and in consecutively enrolled subjects to  assess outcomes generalizability.  
 
Study Design : Prospective, multicenter, single arm st udy with consecutive, eligible subject 
enrollment at each site. All subjects will undergo the Endovascular Aneurysm repair 
procedure with the Nellix System. Sites have  been chosen with a suitable research 
infrastructure and physician experience in endovascular aneurysm repair to ensure 
adequate enrollment. Subjects will be follow ed procedurally to discharge, at 30 days 
(primary safety endpoint), six months, one year (primary effectiveness endpoint) and annually thereafter to five years (total follow-up commitment). 
 Investigators : Physicians (vascular surgeons or interven tional cardiologists/radiologists as part of 
a multi-specialty team with vascular surgeons ) at sites in the United States, and the 
European Union with well-established expe rience in open repair and endovascular 
aneurysm repair techniques (i.e., ≥25 cases in the prior year) may participate. Details 
of the procedural and device usage tec hniques are incorporated into the study 
protocol on the basis of prior experience with an earlier generation device system, and more recent device refinements that have been developed. In those cases where the investigator is an interventionalist,  a vascular surgeon must be immediately 
available during the procedure to perfo rm any necessary surgi cal intervention. 
 
Subject Population : Patients diagnosed with an abdominal aortic or aortoiliac aneurysm who are 
considered candidates for endovascular repa ir and who meet the study eligibility 
criteria may be screened for enrollment in the study.  
 Enrollment: Up to 180 subjects will be enrolled at a ma ximum of 30 sites in the EU, and US in 
the Primary Investigation. This max number includes up to 30 Roll-in subjects and up to 150 patients in the Intent to Treat Pivotal Cohort. In the Primary Investigation, a single site may not enroll more than 15% of the total enrollment. At enrollment closure for the Primary Investigation, an  Extended Investigation will commence at 
these sites to enroll up to 250 additiona l subjects under continued access provisions, 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
23 
 
 
 with the same patient selecton criteria and follow-up schedule and methods. 
Enrollment for this Extended Investigation cohort will occur during the Primary Investigation 1-year data collection.  Enrollment closure of the Extended 
Investigation cohort will occur following completion of FDA review of the Pre-
Market Approval (PMA) Application Submission.  
Training:  Initially, physicians will be directly su pervised in each Nellix case by an Endologix 
trainer or Proctor. This training period will continue until a minimum of one case has been successfully completed and each i nvestigator is cleared to proceed with 
Study enrollment without proctor supervis ion. This training requirement may be 
modified at the discretion of Endologix. 
Inclusion Criteria:  
1. Male or female at least 18 years old;  
2. Informed consent understood and signed;  
3. Patient agrees to all follow-up visits; 
4. Have an infrarenal abdominal aortic  aneurysm (AAA) with maximum sac 
diameter ≥5.0cm, or ≥ 4.5 cm which has increased by ≥0.5cm within the last 
6 months., or
 which exceeds 1.5 times the transverse dimension of an 
adjacent non-aneurysmal aortic segment.   
5. Anatomic eligibility for the Nellix System per the instructions for use : 
a. Adequate iliac/femoral access compa tible with the required delivery 
systems (diameter 6 mm); 
b. Aneurysm blood lumen diameter ≤60mm; 
c. Proximal non-aneurysmal aortic neck: length 10mm; diameter 18 to 
28mm; angle 60° to the aneurysm sac;  
d. Most caudal renal artery to each hypogastric artery length 100mm; 
e. Common iliac artery lumen diameter between 9 and 35mm; 
f. Distal iliac artery seal zone with length of ≥10mm and diameter 
range of 9 to 25mm; 
g. Ability to preserve at least one hypogastric artery. 
h. Ratio of maximum aortic aneurysm diameter to maximum aortic 
blood lumen diameter <1.40 
Exclusion Criteria :  
1. Life expectancy <2 years;                                                                                 
2. Psychiatric or other condition that may interfere with the study;  
3. Participating in another clinical study 
4.  Known allergy to device any device component; 
5. Coagulopathy or uncontrolled bleeding disorder;  
6. Ruptured, leaking or mycotic aneurysm;  
7. Serum creatinine level >2.0mg/dL;  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
24 
 
 
 8. CVA or MI within three months of enrollment/treatment;  
9. Aneurysmal disease of the descending thoracic aorta;  
10. Clinically significant mural thrombus within the proximal landing zone 
(minimum 10mm) of the infrarenal non-aneurysmal neck (>5mm thickness over >50% circumference);  
11. Connective tissue diseases (e.g., Marfan Syndrome) 
12. Unsuitable vascular anatomy;  
13. Pregnant (females of childbearing potential only). 
 
Primary  
Endpoints: Safety : Major adverse events at 30 days.
†  
 Effectiveness : Treatment Success at 1 year.  
This is defined as procedural technical success and the absence of:   Abdominal aortic aneurysm rupture;  
 Conversion to open surgical repair;   
 Endoleak Type I or Type III at 12 months 
 Clinically significant migration
‡;  
 Aneurysm enlargement; or  
 Secondary endovascular procedure up to  12 months for resolution of:  
o Endoleak (Type I or Type III)  
o Device occlusion (may be due to thrombus or other causes)  
o Device migration  
o Abdominal aneurysm sac expansion  
o Device defect.‡ 
 
Additional  
Evaluations: Additional evaluations include: 
 Procedural and in-hospital evaluations:  
o Anesthesia time;  
o Fluoroscopy time;  
o Contrast volume used;  
o Total procedure time; 
o Estimated blood loss; 
                                                      
†Defined as all-cause death, bowel ischemia; myocardial infarcti on, paraplegia, renal failure, re spiratory failure, stroke, and   
 procedural blood loss >1,000cc. Refer to protocol § 8.8.1 .for detailed definitions. 
‡Refer to protocol § 8.8.1  for detailed definitions. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
25 
 
 
 o Incidence of transfusion;  
o Time in ICU;  
o Time to hospital discharge. 
 Mortality (all-cause and aneurysm-related ) within 30 days, at 6 months, and 
annually to 5 years; 
 MAE Individual Components within 30 days, at 6 months, and annually to 5 years 
 Composite Major Adverse Events at 30 da ys, 6 months, and annually to 5 years; 
 Aneurysm rupture within 30 days, at 6 months, and annually to 5 years; 
 Conversion to open repair w ithin 30 days, at 6 months, and annually to 5 years; 
 Adverse Events: All serious and non-serious  events within 30 days, at 6 months, 
and annually to 5 years; 
 Device performance (aneurysm sac diameter change from the first post-operative 
CT scan; device migration; incidence of endoleak) at 30 days, 6 months, and annually to 5 years; 
 Renal function as assessed by estimated glomerular filtration rate (eGFR) pre-
discharge and at 30 days, 6 months, and annually to 5 years; 
 Device Patency and Integrity at 30 days , 6 months, and annually to 5 years; 
 Luminal Thrombus Requiring Intervention at 30 days, 6 months, and annually to 
5 years 
 Secondary endovascular procedure or open surgery within 30 days, at 6 months, 
and annually to 5 years for resolution of endoleak (Type I or III), device 
occlusion, migration, aneurysm sac expansion and/or a device defect. 
 
Schedule of Tests: Pre-procedural high resolution, contrast-e nhanced CT scan evaluation to determine 
anatomical eligibility for enrollment will be performed within three months of the 
study procedure. Following EC/IRB approva l of the study and the written informed 
consent form, patients will be screened for e ligibility. Following informed consent, 
a physical exam and laboratory testing will be performed prior to the procedure. 
Subjects will be followed procedurally and to hospital discharge, and will then be 
followed at intervals: 30 days; 6 months; 1 year; and annually to 5 years.   
Statistical 
Considerations : Study Population : The Intent To Treat (ITT) populati on in this study consists of all 
subjects who are enrolled with an attempt to implant the Study Device. All roll-in 
subjects will be evaluated as a separate grou p. The subject is considered enrolled 
when the study device enters the access vessel.  
The Per Protocol (PP) population in this stud y consists of all ITT subjects that have 
a device implanted and are alive when exiting the procedural room. 
The Completed Cases (CC) population cons ists of all PP subjects that have 
completed 12 month follow-up visit. 
Study Success, Safety : The primary safety analysis is Major Adverse Events (MAE) , 
as previously defined. The primary endpoint is to show that the percentage of subjects with an MAE is statistically superi or to that in the Society for Vascular 
Surgery (SVS) open surgical control group at 30 days (56%). The hypothesis test 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
26 
 
 
 will be evaluated by the exact test as a one-tailed test, using significance level 
α=0.025. Multivariable analyses will be u sed to assess predictors of success.  
Study Success, Effectiveness : The primary effectiveness analysis is Treatment 
Success , as previously defined. The primary e ndpoint is to show that the proportion 
of subjects with Treatment Success is statistically superior to the target rate of 80% at one year. The hypothesis test will be evaluated using the exact binomial 
distribution as a one-tailed test, using significance level α=0.05. Multivariable 
analyses will be used to assess predictors of success.  
Additional Evaluations : Appropriate statistical methodology will be used to analyze 
all additional evaluations.  
4. TRIAL OVERVIEW 
4.1. OBJECTIVE  
The objective of this study is to assess the safety and effectiveness of the Endologix Nellix® 
EndoVascular Aneurysm Sealing System for the endov ascular repair of infrarenal abdominal aortic 
aneurysms (AAA). Procedures will be performed per the Nellix Instructions For Use (IFU) and per 
institutional protocols and standard of care for endov ascular aneurysm repair. As such, this study will 
evaluate the safety and effectiveness of this device system among a wide range of physicians and in 
consecutively enrolled subjects to  assess outcomes generalizability. 
4.2. BACKGROUND  
Mortality due to AAA rupture ranks 13th in the United States and 10th in Canada among men older than 
65 years.* In addition, several authors have suggested an increase in the mortality rate due to rupture of 
AAA in the past decades in both th e United Stated and England, with more than 14,000 and 7,259 
deaths/year in those respective countries.†,‡ Despite being significant, such figures are probably 
underestimated, because many deaths resulting from rupt ured aneurysms are not verified by autopsy, 
and are consequently not documented.§ Some researchers have reported that the overall lethality 
associated with rupture of AAA approaches 80%, including dead on arrival subjects or those who die 
before the diagnosis is made.**  
                                                      
*Semenciew R, Morrison H, Wigle D,  et al.  Recent trends in morbidity and mortality rates for abdominal aortic aneurysms. Rev 
Canadien Santé Publique 1992;83:274-6. 
†Lelienfeld DE, Gurdenson PD, Spra fka JM, et al. Epidemiology of aortic aneurysms: Mortality tr ends in the United States 1951-
1981 . Atherosclerosis 1987; 7:637-43. 
‡Fowkes FRG, Macintyre CCA, Rucjerley CV. Increasing incidence of aortic aneurysms in England and Wales. Brit Med J 
1989;298:33-5. 
§Quil DS, Colgan MP, Summer DS. U ltrasonic screening for the detection of abdomin al aortic aneurysms. Surg Clin North Am 
1989;69:713-20.  
**Bengtsson H, Bergqvist D.  Ruptured abdominal aortic an eurysm: a population-based study.  J Vasc Surg 1993; 18:74-80. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
27 
 
 
 AAA is defined clinically as a focal dilatation of th e aorta causing a diameter increase of >50% of the 
expected normal diameter.* Although any artery may develop an aneurysm, they are most commonly 
observed in the infrarenal abdominal aorta, thoracic aorta, popliteal artery and common iliac artery.   
The principal risks related to aneurysms are ruptur e and thrombus migration. Aneurysms slowly and 
continually increase in size leading to the aneurysm rupture. The la rger an aneurysm becomes, the 
likelihood of eventual rupture increases. The natura l history of aortic aneurysms is to enlarge and 
rupture. Other potential complications of the aneu rysm include compression of adjacent organs which 
may result in aortoenteric fistula, or aortocaval fistula. If the thrombus embolizes and flows down the 
blood stream, this can induce acute or chroni c arterial obliteration of the lower limbs.   
The risk of rupture is weighed against the risk of perioperative morbidity.  The United Kingdom Small 
Aneurysm trial (UKSAT) reported 103 aneurysm ruptures in 2,257 subjects over a period of seven 
years, with an annual rupture rate of 2.2%.† The decision to treat a patient that presents with an 
asymptomatic aneurysm is primarily dependent upon  the size of the aneury sm. Current Society for 
Vascular Surgery (SVS) practice guidelines recommend su rveillance for most subjects with a fusiform 
AAA in the range of 4.0 to 5.4cm in maximum diam eter; therefore, surgical repair of abdominal 
aneurysms of 5.5 cm or greater in diameter is reco mmended in healthy subjects, as is repair of saccular 
aneurysms. There are a number of qualifiers with in the SVS guidelines that recommend AAA repair at 
5.0cm, such as rapidly expanding aneurysms, and women.   
It is estimated that approximately 25% to 40% of infrarenal AAA are not suitable for endovascular 
aneurysm repair (EVAR) due to unfavorable proxima l neck anatomy (e.g., highly angulated, dilated, 
short, or encroaching on or involving the renal arteries.‡,§  In most studies of endovascular AAA repair, 
the infrarenal non-aneurysmal neck length and angul ation to the aneurysm sac requirements are ≥15mm 
and ≤60°, respectively; shorter lengths or greater angula tion have been reported to increase the risk of 
migration and type 1A endoleak a nd associated need for intervention.**,†† 
When selecting the specific stent graft to be used for EVAR, the characteristics of the graft must be 
considered in light of the patient’s anatomic and physiologic characteristics. Endovascular devices vary 
in the type of stent design. For example, most of  the currently available devices seal aneurysm by 
proximal and distal fixation of the stent graft by e ither active fixation (anchoring pins) or oversizing 
the stent diameter for increased radial force th ereby achieving seal and excluding the aneurysm sac 
                                                      
*Hallett JW Jr. Diseases of the aorta and its branches – aneurysms. Merck Ma nual, Online Medical Manual (2008). Retrieved on 
19March2010 from http://www.merck.co m/mmpe/sec07/ch079/ch079b.html.  
†Mortality results for randomized controlled  trial of early elective surgery or u ltrasonographic surveillance for small abdomina l 
aortic aneurysms Lancet 1998; 352:1649-55.  
‡Carpenter JP, Baum RA, Barker CF, et al. Impact of exclusion criteria on patient selection for endovascul ar abdominal aortic 
aneurysm repair. J Vasc Surg 2001;34:1050-4.  
§Arko FA, Filis KA, Seidel SA, et al. How many patients with  infrarenal aneurysms are candidates for endovascular repair? J 
Endovasc Ther 2004;11:33-40. 
**Leurs LJ, Kievit J, Dagnel ie PC, et al. Influence of infrare nal neck length on outcome of endova scular abdominal aortic aneurys m 
repair.  J Endovasc Ther 2006;13:640–8. 
††AbuRahma A, Campbell J, Stone PA, et al. The correlation of aortic neck length to  early and late outcomes in endovascular repai r 
patients. J Vasc Surg 2009;50:738-48. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
28 
 
 
 lumen. Greater than 25% of subjects develop an endoleak (mostly type II endoleaks due to back-
bleeding of lumbar or visceral arteries within the aneurysm sac) within the first two years following 
endoluminal stent-graft repair,* and approximately 15-20% of the endoleaks persist at five years.8 
Endoleaks may lead to sac enlargement and migrati on and may require reintervention, using either 
catheter-based techniques or conversion to open re pair. These secondary procedures increase the risk 
to the patient and increase the cost of treatment.†  Accordingly, EVAR subjects are routinely monitored 
annually by contrast-enhanced CT scan after trea tment contributing further to treatment costs and 
increasing patient exposure to nephrotoxic contrast agents and radiation. Recent reports suggest 
contrast nephrotoxicity affects 7 to 12% of subjects after CT angiography.‡ 
The Nellix System was designed to withstand the mi gration and lateral disp lacement forces acting on 
endografts, while at the same time  excluding the aneurysm sac lume n and minimizing endoleaks of any 
kind. The system is comprised of two independent flow channels, one to each iliac artery. Each flow 
channel consists of a balloon-e xpanded ePTFE covered stent surrou nded by a Polymer-filled EndoBag 
which fills the blood lumen within the aorta, thus providing positional stability of the endograft and 
sealing the aneurysm completely from side-branch flow.§ A clinical trial has been performed to assess 
the safety and effectiveness of the first generati on Nellix system for endovascular AAA repair and 
results serve as the basis for CE Mark approval (Oct ober 2012); initial results to one year have been 
reported.** Results of this trial demonstrate the versatility of the Nellix System in treating a variety of 
AAA anatomies, including those that have common iliac artery involvement bilaterally. 
Continued clinical evaluation of the Nellix System in a broader group of institutions and physicians is 
therefore appropriate to assess the safety and e ffectiveness of the device for AAA repair and the 
generalizability of the approach.  
4.3. STUDY DESIGN  
This is a multicenter, prospective, single arm clin ical study. Subjects with infrarenal AAA who are 
suitable candidates for endovascular repair us ing the Nellix System, based on protocol 
Inclusion/Exclusion criteria, will be considered for enrollment. 
After this protocol and the patient informed consent form are reviewed and approved by the local Ethics 
Committee/Institutional Review Board (EC/IRB), patients having infrarenal AAA will be offered 
participation in the study. This will be accomplishe d through the patient’s reading of the informed 
consent form in the patient’s native language and discussion of the study with the patient by the 
Principal Investigator (PI) and site personnel. Agreem ent to participate and to attend all follow-up visits 
                                                      
*Stavropoulos SW and Charagundla SR. Imaging techniques for de tection and management of endoleaks after endovascular 
aortic aneurysm repair. Radiology 2007; 243(3):641-55.  
†Vogel TR, Symons RG, Flum DR. Longitudina l outcomes after endovascular repair of  abdominal aortic aneurysms. J Vasc 
Endovasc Surg 2008;47(2):264-9.  
‡Chaer RA, Gushchin A, Rhee R, et al. D uplex ultrasound as the sole long-term surve illance method post-endovascular aneurysm 
repair: a safe alternative for stable aneurysms. J Vasc Surg 2009; 49:845-9.  
§Donayre CE, Zarins CK, Krie vins DK, et al. Initial clinical experience with a sac anchoring endoprosthesis for abdominal aortic  
aneurysm repair. J Vasc Surg 2011;53:574-82. 
**Krievins DK, Holden A, Savlovskis J, et al. EVAR using th e Nellix sac anchoring endoprosthes is: treatment of favorable and 
adverse anatomy. Eur J Vasc Endovasc Surg 2011;42:38-46. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
29 
 
 
 will be documented with the patient ’s signature on the informed consent form, with appropriate 
signatures of the site PI and an impartial witness. 
After providing written informed consent, screening and eligibility determinations will be performed 
by the site, Core Lab, Independent Anatomical Ev aluation and Endologix. Subjects will undergo a high 
resolution, contrast-enhanced computed tomography a ngiography (CT) scan of the relevant aortic and 
aortoiliac vasculature within three months of the scheduled procedure. Evaluation of the aortic and 
vascular anatomy suitability per this protocol, as depi cted on the CT scan, will be performed by the site 
PI and by an independent core laboratory and will undergo independent  medical evaluation. Other tests 
include a physical examination, review of medical  history for exclusionary conditions, and selected 
blood laboratory analyses. Endologix will notify, in  writing, each potential patients final eligibility 
status before a case may be scheduled. 
Following discharge from the hospital, the first follo w-up visit will be made at 30 days (±2 weeks). A 
CT scan will be performed to assess aneurysm morpho logy and device integrity and patency, as well 
as the status of the implanted devices. Subsequent follow-up visits will be made at six months, one 
year, and annually to five years per institutional standard of care for subjects with endovascular stent 
grafts. Enhanced post-operative follow- up visits are discussed in protocol §8.5.6 . Continued subject 
follow-up beyond five years is outside of the scope of  this study. Nonetheless, all subjects should be 
monitored and evaluated per the institutional sta ndards of care for patients with an implanted 
endovascular stent graft.  
5. STUDY POPULATION 
5.1. PRIMARY INVESTIGATION  
Up to 30 sites in the EU, Canada, and the United St ates will enroll up to 180 subjects including 30 Roll-
in subjects and up to 150 patients in the Intention to Treat Pivotal Cohort for endpoint analysis. Total enrollment at a single site is restricted to 15% of the Pivotal Cohort. Following investigator training, 
each PI will commence patient screening and enroll ment under approval per applicable national and 
local clinical trial requirements
* and complete a minimum of one (1) successful Nellix case (Roll-in) 
in their training phase. This training period may be m odified at the discretion of Endologix. Physicians 
will be directly supervised in each case by designated Endologix staff.    Pivotal Cohort:  Up to 150 subjects will be enrolled at a maximum of 30 sites in the US and the EU. 
This includes the statistically justified sample si ze of 132 plus an allowance for deviations from 
assumptions.   
 
Roll-In Cohort:
 One (1) roll-in subject may be enrolled per site, therefore a maximum of 30 enrolled in 
the study, to allow for Investigator(s) to receive additional training on the Nellix System. Any roll-in 
subjects will be screened, consented, treated and followed identically to the main study cohort. 
However, the roll-in cohort of this study will be evaluated separately.   
                                                     
 
* Commercially approved clinical trial requirements in the EU  (CE Mark), IDE approval in th e US, and ITA approval in CA 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
30 
 
 
 5.2. EXTENDED INVESTIGATION  
Sites that participated in the Primary Investiga tion will be invited to participate in an Extended 
Investigation after enrollment closure of the primar y investigation. This Extended Investigation will 
permit study site continued access to the Nellix Syst em through the Primary Investigation’s completion 
of the primary safety and effectiveness endpoint, and FDA review of the premarket approval (PMA) 
Submission. It is estimated that this Extended Investigation (Continued Access) phase will enroll an 
additional 150 patients.  
Continued Access Cohort: Up to 250 patients will be enrolled in to the Extended Investigation based on 
an enrollment rate of 0.5 patients per site per m onth and an estimated 20 months from the close of 
enrollment in the Primary Investigation. Enrollmen t in Extended Investigation (continued access) phase 
will be limited to the 27 US sites only as the Nelli x System is commercially available to the three 
participating European sites. 
 
5.3. I
NCLUSION CRITERIA  
A patient who meets all of the following criteria  potentially may be included  in the study: 
1. Male or female at least 18 years old; 
2. Informed consent form understood and signed and patient agrees to all follow-up visits; 
3. Abdominal aortic aneurysm with sac diameter ≥5.0cm, or ≥4.5cm which has increased by ≥0.5cm 
within the last 6 months,  or  or which exceeds 1.5 times the transverse dimension of an adjacent 
non-aneurysmal aortic segment. 
4. Anatomically eligible for the Nellix System (per Instructions For Use): 
a. Adequate iliac/femoral access compatible with  the required delivery systems (diameter 
6 mm); 
b. Aneurysm blood lumen diameter ≤60mm; 
c. Proximal non-aneurysmal aortic neck:  
i. length 10mm; 
ii. diameter 18 to 28mm;  
iii. angle 60° to the aneurysm sac;  
d. Most caudal renal artery to each hypogastric artery length 100mm; 
e. Common iliac artery lumen diameter between 9 and 35mm; 
f. Distal iliac artery seal zone with length of ≥10mm and diameter range of 9 to 25mm; 
g. Ability to preserve at least one hypogastric artery. 
h. Ratio of maximum aortic aneurysm diameter to maximum aortic blood lumen diameter 
<1.40  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
31 
 
 
 5.4. EXCLUSION CRITERIA  
A patient who meets none of the following  criteria potentially may be included  in the study: 
1. Life expectancy <2 years as judged by the Investigator; 
2. Psychiatric or other condition that may interfere with the study; 
3. Participating in another clinical study; 
4. Known allergy or contraindica tion to any device material; 
5. Coagulopathy or uncontrolled bleeding disorder;  
6. Ruptured, leaking or mycotic aneurysm;  
7. Serum creatinine (S-Cr) level >2.0 mg/dL; † 
8. CVA or MI within three months of enrollment/treatment;  
9. Aneurysmal disease of the descending thoracic aorta;  
10. Clinically significant mural thrombus within the proximal landing zone (minimum 10mm) of the 
infrarenal non-aneurysmal neck (>5mm th ickness over >50% circumference);  
11. Connective tissue diseases (e.g., Marfan Syndrome); 
12. Unsuitable vascular anatomy that may interfe re with device introduction or deployment; 
13. Pregnant (female of childbearing potential only). 
6. RESPONSE MEASURES 
6.1. PRIMARY SAFETY  
The safety endpoint is defined as the incidence of Major Adverse Events (MAE) at 30 days, defined 
as the composite of the following. Event definitions are provided in § 8.8.7  
 All-Cause Mortality ; 
 Bowel Ischemia ; 
 Myocardial Infarction ; 
 Paraplegia ; 
 Renal Failure ; 
 Respiratory Failure ; 
 Stroke;  
 Procedural Blood Loss ≥1,000mL  
 
Refer to §10.6 for primary safety endpoint analysis details. 
                                                      
†This criterion does not apply to  patients on dialysis prior to  study screening/enrollment. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
32 
 
 
 6.2. PRIMARY EFFECTIVENESS  
The primary effectiveness endpoint is defined as the rate of Treatment Success at one year. Treatment 
Success is a composite of outcomes clinically relevant  to the endovascular repair of infrarenal AAA as 
follows. Event and related definitions are provided in § 8.8.7.  
Treatment Success: Procedural technical success ¥ and absence of:  
 Abdominal aortic aneurysm rupture;  
 Conversion to open surgical repair; 
 Endoleak Type I or III at 12 months; 
 Clinically significant migration‡;  
 Aneurysm enlargement; or  
 Secondary endovascular procedure up to  12 months for resolution of  
 Endoleak (Type I or Type III)  
 Device obstruction or occlusion  
 Device migration  
 Abdominal aneurysm sac expansion  
 Device defect.‡ 
 
 
Refer to §10.7 for primary effectiveness endpoint analysis details. 
 
                                                      
¥ Procedural technical success is deployment of the Nellix System in the planne d location and without unintentional coverage of 
both internal iliac arteries or any visceral aortic branches and with the removal of the delivery system. 
‡Refer to protocol § 8.8.1  for detailed definitions. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
33 
 
 
 6.3. ADDITIONAL EVALUATIONS  
Additional evaluations include: 
 Procedural and In-Hospital Evaluations :  
o Volume of contrast media used; o Estimated blood loss; 
o Fluoroscopy time; o % requiring blood transfusion; 
o Total procedure time;‡ o Anesthesia time;¥ 
o Time in ICU;§  o Time to hospital discharge;₤  
 Mortality , all-cause and aneurysm-related, within 30 da ys, at 6 months, and annually to 5 years; 
 MAE Individual Components  within 30 days, at 6 months, and annually to 5 years; 
 Composite MAEs  after 30 days, at 6 months, and annually to 5 years; 
 Aneurysm Rupture within 30 days, at 6 months, and annually to 5 years; 
 Conversion to Open Surgical Repair within 30 days, at 6 months, and annually to 5 years;  
 Adverse Events  (serious and non-serious) within 30 days, at 6 months, and annually to 5 years;  
 Device Performance (aneurysm sac diameter change from th e first post-operative visit; device 
migration; clinically significant device migration, incidence of endoleak) at 30 days, 6 months, and 
annually to 5 years;  
 Renal Function pre-discharge and at 30 days, 6 months, and annually to 5 years, as assessed by 
the estimated glomerular filtration rate (eGFR) and changes over time;  
 Device Patency and Integrity within 30 days, at 6 months, and annually to 5 years,  as determined 
by contrast-enhanced CT scan, and as assessed by the independent core laboratory, inclusive of:  
o Patent luminal flow  o Absence of kinking or occlusion  
o Absence of stent fracture o Absence of device failure 
 Luminal Thrombus Requiring Intervention within 30 days, at 6 months, and annually to 5 
years;  
 Secondary Procedure  within 30 days, at 6 months, and annually to 5 years for resolution of 
endoleak, device occlusion, migration, aneurysm sac expansion and/or a device defect. 
 
                                                      
‡Elapsed time from the first break of skin to  final closure (i.e., skin to skin time). 
¥Elapsed time from the initiation to the end of the anesthesia protocol. 
§Elapsed time from the first administration of anesthesia to re lease from the ICU or post-anesthesia care unit providing ICU-lev el 
care. If the patient is not admitted to the ICU, this is defined as 0 hours. 
₤Elapsed time from initiation of the procedur e to physical discharge from the hospital. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information cont ained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
34 
 
 
 7. STUDY MATERIALS  
The Nellix System is comprised of four components as further described below:  
1. Nellix Catheters (single use); 
2. Nellix Accessory kit (single use);  
3. Nellix Dispenser (single-use); 
4. Nellix Polymer (single-use). 
7.1. DEVICE DESCRIPTION  
Implanted Devices.  The Nellix implant consists of two de vices, each advanced from the respective 
femoral artery via a catheter-based delivery system over a standard .035” guidewire. Each implanted 
device has the following main components: an e xpanded polytetrafluouroe thylene (ePTFE) covered 
balloon expandable cobalt chromium alloy stent surrounded by a polyurethane EndoBag with welded 
seams and a lumen having an inner polyester (PET) sleeve is attached to the stent proximally and 
distally using polyethylene sutures, and a biostabl e Polymer formulation which is introduced through 
the catheter system to the EndoBag and cures in situ.  
An illustration of the implant procedure is shown be low. Images of the stent (with and without ePTFE 
graft), EndoBag, and the final implant in a silicone model are shown subsequently. 
 
                    
  

Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information cont ained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
35 
 
 
  
 
  
  Stent ePTFE Covered 
Stent 
Stent  EndoBag  Final Implant  
 
The mechanism of action is as follows. The ePTFE c overed stents form lumens through which blood 
flows to the distal limbs and vasculature. The EndoBags with cured polymer exclude the aneurysm 
from blood flow, preventing aneurysm pressurization and rupture. This seals the entire anatomy from 
the infrarenal segment to the orig in of the hypogastric arteries. 
Delivery Systems.  The 17Fr profile (OD) delivery systems are sterile, single use, catheter-based 
systems used to deploy the stents with EndoBag s and are compatible with standard 0.035-inch 
guidewires. All delivery systems are of the same design regardless of stent/EndoBag model. 
Three other single use components complete the Nellix System: 
 Sterile Polymer dual chamber cartridges requiring st orage at or below -20°C until use. Immediately 
prior to use (1-2 hours), the required Polymer cartr idge(s) are thawed per the Instructions For Use 
(IFU). 
 Sterile accessory kit including a console with dual sets of tubing and quick connects for 
simultaneous attachment to two delivery catheters ; two mixers, and a Centurion™ Biomedical 
Compass™.† The mixer attaches to the end of the Polymer cartridge and mixes the two chamber 
solutions during transfer into the EndoBags. A second mixer is provided as a back-up if needed.  
 Polymer dispenser 
The pre-operative high resolution, c ontrast enhanced CT scan serves to determine anatomical measures 
for subject eligibility and device initial sizing determin ations. Arteriography with the aid of a marker 
                                                      
†The pressure monitoring device is ma rketed by Mirador Biomedical, a subsidiary  of Centurion Medical Products, Inc. 
(Williamston, MI, USA) and is CE Marked through LNE G-MED. 

Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
36 
 
 
 catheter bilaterally serves to verify the specific device length needed on each side to ensure full 
coverage of the Nellix device from the infrarenal segment to the supra-hypogastric segments. 
After selected delivery system is introduced throug h femoral arteriotomy under fluoroscopic guidance, 
each is advanced and positioned acro ss the aneurysm sac at the desi red location to place the stents 
below the most caudal renal artery and aligned at their proximal edge. The outer sheath of each delivery 
system is retracted to expose each constrained stent/EndoBag. (Note: A tether wire attaches each 
EndoBag to the catheter. The catheter can be remove d only after disengaging the tether wire. This is a 
safety mechanism designed to hold the implant in place during deployment.) 
At this time, the console is attached to both delivery systems using the mating, color-coded quick 
connects as depicted in the image below. White  connectors denote the EndoBag evacuation and 
Polymer fill line; black connectors denote the stent balloon expansion line; luer connectors denote the 
angiographic media injection line (exiting the ports in the delivery system tip). The .035” guidewire 
lumens are on the outermost ends of the delivery catheter handles. 
 
 
EndoBag evacuation, balloon expansion, Polymer in troduction, and angiographic media injection are 
all performed through the console: 
 A vacuum is applied via console port 1 with the switch in the ‘open’ position to simultaneously 
evacuate air from both EndoBags. After evacuation,  the switch is placed in the ‘closed’ position. 
 An inflation device is attached to control cons ole port 2 to simultaneously balloon expand both 
ePTFE covered stents with contrast enhanced salin e per the IFU. The stents expand from each end 
toward the center. The balloons are then simultaneously deflated per standard technique.  
 The EndoBags are then filled by dispensing Polymer through console port 3 with the pressure 
transducer placed between the mixer and the port 3 luer. Polymer filling of the EndoBags occurs 
simultaneously, and is to continue until the pressure transducer displays a reading of 180mmHg. In 
the case of a patient with systolic blood pressu re exceeding 180mmHg, Polymer filling continues 
to a pressure that is 20mmHg above the patient’s  systolic pressure. Once Polymer is completely 
injected into the EndoBags, the physician will allo w the polymer to cure for approximately 3 to 5 

Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
37 
 
 
 minutes. Polymer curing is visually observable through the window on console port 3, which will 
change in color from red to white when cured. 
A final angiographic run is done to confirm the co mplete seal of the aneu rysm sac and absence of 
endoleaks. If deemed appropriate by  the physician, a secondary fill ma y be performed to add additional 
Polymer to each EndoBag independently. The deliver y systems are then detached from the implant by 
releasing the tether wires, and are removed from the patient and discarded per hospital standard practice. 
7.2. INVESTIGATOR TRAINING AND EXPERIENCE  
Investigators will be directly supervised in each case by an Endologix trainer or a certified Proctor 
until a minimum of one Nellix case have been successf ully completed.  One Principal Investigator 
(PI) at each participating site will be responsible for supervision of study conduct.   He/she and any 
authorized sub-investigator must satisfy the followi ng criteria prior to the enrollment of their first 
patient.  
1. Complete review of prior clinical safety and effectiveness information regarding the earlier 
generation device, as well as design qualification t esting regarding the Nellix System under study, 
and the scientific literature review. 
2. Have prior training and experience in the open surgical or endovascular repair of AAA 
(approximately ≥25 cases as an institutional team, in the prior year). 
3. Undergo didactic training on the device anatomy and design, Instructions for Use (IFU) including 
patient selection criteria, contraindications, wa rnings, precautions, and proper device use, and 
troubleshooting methods. 
4. Practice using the Nellix System in a simulated use bench top model. Completion of each criterion 
will be documented for each PI and site prior  to performance of the first clinical procedure at a 
given site under this protocol. S ub-Investigators will also be require d to meet training requirements.  
This may be completed at a late r date per Endologix discretion. 
 
For procedures lead by a sub-investigator, the PI  is expected to be present to provide proper 
supervision of the case, unless the sub-Investigator has been through inves tigational device training 
and approval by Endologix. 
 
Roll-In Subjects:  
Once the study formally initiates one (1) roll-in subject per site may be enrolled to allow for 
Investigator(s) to receive additional training on the Nellix System. This requirement may be waived at 
the discretion of Endologix for sites that have pr ior experience with the Nellix System. Any roll-in 
subjects will be screened, consented, treated and followed identically to the main study cohort. 
However, the roll-in cohort of this study w ill be evaluated as a sepa rate feasibility group. 
7.3. DEVICE ACCOUNTABILITY  
Usage of the Nellix System will be documented in the electronic Case Report Forms (eCRF) and within 
an Investigational Device Accountability Log.  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
38 
 
 
 In the case of a device malfunction prior to implanta tion, the information will be noted in the eCRFs 
and all device components must be returned to En dologix. Should the device be removed from the 
body, the device should be returned to Endologix fo r evaluation per the IFU. Usage of the devices will 
be documented in the eCRFs and on the site’s inventory log. 
7.4. PATIENT AND DEVICE PREPARATION  
All procedures must be performed in an operating ro om, or in an endovascular suite having full imaging 
capabilities, vascular surgery and anesth esia services. The PI will refer to institutional protocols relating 
to anesthesia and monitoring of vital signs. The a ppropriate devices will be selected in accordance with 
the patient eligibility determination. The devices will  be prepared and handled in accordance with the 
IFU, which is provided in Attachment 1 .† Other ancillary devices will be selected by the physician per 
institutional standards.  
8. STUDY METHODS 
8.1. GENERAL ENTRY PROCEDURES  
Prospective subjects as defined by the criteria in §5. 2 will be considered for entry into this study.  
All site personnel involved in patient screening and data collection procedures will be trained on this 
protocol and the electronic remote data captu re (eDC) system. Following patient consent, 
inclusion/exclusion criteria information will be en tered into the eDC system. This action will notify 
Endologix that a patient has been consented and is be ing considered for enrollment. In parallel, the pre-
operative CT scan will be uploaded to Core Lab by the site.  The Core Lab will subsequently  provide 
the anatomical measurement s for confirming eligibility. Endologix will then facilitate an independent 
clinician review of anatomical and medical informa tion for final sign off.  Sites will be notified of 
individual study subject eligibility via the EDC system. 
8.2. INFORMED CONSENT  
Written informed consent, in accord ance with applicable Good Clinical Practice standards and study 
center regulations, shall be obtained from each patient , or from their legal representative, prior to the 
study procedures. The PI will retain a copy of the signed informed consent do cument in each patient’s 
record, and provide a copy to the patient.  
The PI must not request the written informed consen t of any patient, and must not allow any potential 
patient to participate in the investigation before obtaining governing EC/IRB approval.  
Attachment 2  provides a template of the consent form that  may be used. The sample form contains the 
minimal consent language content that must be in corporated into the Info rmed Consent document. 
Other elements may be added or minor language chang es may be made for clarity by the PI or by the 
EC/IRB, but substantial cont ent may not be deleted. 
                                                      
†Ancillary devices recommended for use durin g the procedure are listed in the IFU. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
39 
 
 
 Prior to starting the study, the PI will provide Endo logix with a copy of the sample Informed Consent 
document approved by the EC/IRB with documente d evidence that the EC/IRB has approved the 
protocol. 
 
8.3. SUBJECT IDENTIFICATION  
Upon satisfactory completion of a ll site start-up training and docum entation requirements, Endologix 
will supply the site with written ‘Go’ notification that initiation of subject screening/consenting for 
study enrollment is authorized. 
Subject numbers will be automatically assigned by the EDC system. 
A Screening Log will be maintained by the site, ei ther on paper or electronically in the EDC, to 
document each subject who undergoes the screening process and the determination of eligibility. 
The actual procedure date will serve as the “start”  date from which follow-up evaluations will be 
measured. After treatment, each patient will be evalua ted prior to hospital discharge and will then be 
evaluated at one month (defined as 30 ± 14 days), at six months (defined as 180 ± 30 days), and at 
annual follow-ups at 1 year (defined as 365 ± 60 days), and at 2 to 5 years (± 90 days). 
8.4. SCHEDULE OF MEASUREMENTS  
A summary of the tests and measurements to be con ducted pre-study/at baseline, operatively, prior to 
discharge, and during follow-up is illustrated in the following chart: 
Schedule of Tests : Screening/ 
Baseline Procedure 
(Day 0) Pre-
Discharge 1  
Mo. 
± 14 days  6  
Mo. 
± 30 days  Every 6 
months 
(Enhanced 
Follow-up)£ 1  
Yr. 
± 60 days  2 to 5  
Yrs. 
± 90 days  
Inclusion/Exclusion  x        
Demographics/Medical History  x        
Physical Exam†  x  x x x x x x 
Blood Labs‡ x  x x x  x x 
Contrast-enhanced CT scan¥ x   x x x x x 
Procedural Information   x       
Adverse Events  x x x x x x x 
 †The physical exam includes overall health, physical assessment, and vital signs.  
‡Blood labs include serum creatinine and hemoglobin.  
¥The baseline high resolution, contrast-enhanced  CT scan performed within the prior thr ee months will be performed to determine 
anatomical eligibility. 
 £Subjects who experience migration, AAA sac enlargement and/or a Type  1A or 1B endoleak or subjects who are considered at risk a re 
recommended to be followed every 6 months. 
  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
40 
 
 
 8.5. STUDY PROCEDURES AND EVALUATIONS  
8.5.1.  Informed Consent 
The patient, or his/her legal representative, is to  be informed about the study and provide written 
consent. Confirmation of written consent will be entered in the eCRF for verification by the 
Sponsor prior to enrollment eligibility determination. Please see attachments  of the informed 
consent template and the study eCRFs.  
8.5.2.  CT Scan Protocol 
Patient enrollment into this study is based on the site evaluation of patient conformance with the 
protocol-specified selection criteria (§5.2), including anatomical requirements for the device 
based on the high resolution (slice thickness minimum ≤3mm; axial, coronary, sagittal views), 
contrast-enhanced CT scans. To ensure cons istency, below are the requirements for CT 
acquisition: 
 Only high resolution, contrast-enhanced  spiral CT scans are acceptable.  
 Data must be uncompressed. 
 Preferred maximum slice spacing is 2mm. In no case should it exceed 3mm . 
 The preferred protocol, shown below, is easier  to attain with a multi-row scanner. If the 
preferred protocol cannot be used, an  alternate protocol is provided. 
 Instruct patient not to move during scan. Do not move table height, position, or field of 
view during scan. If such movement occurs, repeat scan in its entirety. 
 Parameter Preferred Alternate 
Scan Mode Helical/Spiral 
Scan Parameters 140kVp, Auto mA, 0.5sec 140kVp, 280mA (min), 1.0sec 
Collimation 0.625 to 2mm 3mm 
Slice Spacing 0.625 to 2mm 3mm 
Superior Extent Superior to the celiac artery origin 
Inferior Extent Lesser trochanter of femur 
Patient Instruction Single breath hold 1st hold: above celiac to bifurcation 
2nd hold: bifurcation to lesser trochanter 
Contrast Standard non-ionic 
Volume and Rate 150mL at 3 to 4 mL/sec or as per institutional standards 
Scan Delay ROI - threshold 90Hu in aorta 
Field of View Large body 
Window Level 400/40 

Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
41 
 
 
 8.5.3.  Pre-Operative Activities 
Following informed consent, the SCREENING AND BASELINE eCRFs are to be completed.  The 
PI is to proceed with procedure scheduling only after receiving acknowledgement from 
Endologix that the patient meets the enrollment criteria. This determination is based on the 
documented responses and data provided by th e PI, the Core Lab CT assessment and the 
independent medical review. 
8.5.4.  Subject Enrollment 
Enrollment in the study only occurs upon advancement of the study device into the subject’s 
vasculature. Therefore, the date of study enrollmen t is the date of the Nellix System implant, 
as documented in the Visit Date field in the Index Procedure eCRF. If the device does not 
contact the patient, the patient will be consid ered as screen failure and the assigned study 
number will not be given to another patient. If, during the index procedure, the device is 
introduced but is not implanted and/or there is conversion to open surgery, the patient will be 
followed until the 30 day follow-up. 
8.5.5.  Post-Operative Follow-up Visits 
The eCRFs are to be entered for each subject at  the post-operative follow-up visits.  These visits 
should be scheduled post-procedurally at 30±14 days (one month visit),  180±30 days (six month 
visit), 365±60 days (one year visit),  730±90 days (two year visit),  1095±90 days (three year 
visit),  1460±90 days (four year visit),  and 1825±90 days (five year visit).   
8.5.6.  Enhanced Post-Operative Follow-up Visits 
Subjects who experience migration, AAA sac enlarg ement and/or a Type 1A or 1B endoleak or 
who are at risk of experiencing any of these events are recommended to be followed every 6 
months. “At risk” is defined as those subjects who would not meet the new inclusion/exclusion 
criteria, or those subjects with an inadequat e procedure, based on current understanding of 
Nellix implantation best practices.  Specifically, procedures resulting in low placement of the 
device, or lack of adequate proximal or di stal seal, are now considered an inadequate 
procedure. An inadequate procedure is defined  as not meeting any one of the following: 
1. (CoreLab Proximal Seal – 4 mm) ≥ 10 mm 
2. Acquired distal seal ≥ 10 mm 
3. Lowest stent within 10 mm of the lowest renal artery 
 Please reference the Schedule of Measurements  §8.4 for a summary of tests and measurements 
to be performed at the enhanced follow-up visit   
Please note: notification of at-risk subjects provi ded to each site Principal Investigator.   
Instructions for eCRF completion and the study -required evaluations for each visit will be 
provided at the site initiation visit.  
   
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
42 
 
 
 8.6. RECOMMENDED SECONDARY INTERVENTION TREATMENT OPTIONS (ALSO KNOWN AS 
BAILOUT PROCEDURES ) 
Endologix submitted an Unanticipated Adverse Device Effect (UADE) report to the FDA on 
October 14, 2016 to report higher than anticipated  rates of migration, endoleak (Type IA), and 
AAA sac enlargement, based on the 2-year follow- up data from the Nellix US IDE trial.  As 
part of the investigation of the higher than an ticipated rates of Type 1A endoleaks, migration 
and AAA sac enlargement, Endologix, in consulta tion with physicians, reviewed alternative 
treatment options from clinical studies, commerc ial use, literature, ph ysician experience and 
use in similar technologies (e.g., EVAR) to deve lop a list of recommended treatment options.  
For many of the treatment options, the clinical data to support the safety and effectiveness of the treatment is limited. 
 
 
The treating physician should consider multiple factors such as subject anatomy, subject risk 
profile, hospital standard of care and physician  preference when determining the appropriate 
treatment option. Endologix’s treatment recommenda tion is based on a subset of those factors, 
and as such, should be used as a reference fo r physicians and not a requirement. Each 
secondary intervention case requiring an additi onal Nellix device will undergo an internal 
review process. Implanting physicians in such cases will go through device training  prior to 
their first bailout procedure and a proctor w ill be provided for secondary ChEVAS procedures. 
The recommended treatment options are provided below.  It should be noted conversion to open repair should be used if a less invasive option is not 
feasible for the subject, based on the physician’ s clinical judgment.  Even with the other 
recommended treatment options available, conversi on to open repair can be performed at any 
time, per the physician’s discretion. 
 
8.6.1.  Treament Options for Type 1 Endoleaks 
8.6.1.1.  Type 1A Endoleaks 
The recommendation for treatment of Type 1A endoleaks is based on evaluation of the 
implant position and proximal seal zone. The Nellix  implant is correctly aligned if the bottom 
of the first stent cell element is aligned with th e distal origin of the most caudal renal artery 
and the second stent not more than one stent st rut higher on the opposite side.  The Nellix 
implant has an adequate proximal seal zone if  at least 10mm of the Nellix Endobags are in 
contact with healthy (i.e. minimal tortuosity, occlusive disease, and/or calcification)  aortic proximal neck vessel wall.  The length of the aortic proximal seal is measured from the lower margin of the most caudal renal artery to the point distally where the lumen diameter change 
is 10%.  Based on evaluation of these factor s, two potential treatment options for the 
treatment of Type 1A endoleaks have been identified: 
 Coils (see Appendix A on page 68  for list of recommended coils) and liquid 
embolics (Onyx®) with or without proxi mal covered stent extenders (balloon-
expandable or self-expanding)  
 Nellix proximal extenders with or without co mmercially available stent grafts in the 
visceral arteries (NiNA with polymer/ Secondary ChEVAS) o Covered stents are placed in the visceral arteries to allow blood flow and the 
Nellix implant is placed in a sufficient le ngth of healthy supra-renal aortic neck 
to enable aneurysm sealing. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
43 
 
 
  
The table below summarizes these options, a ligning each with evaluation criteria: 
 
Implant and Anatomic 
Evaluation Criteria  Potential Treatment Options for Type IA Endoleaks 
Implant positioned correctly with 
adequate sealing zone ‐ Coils* and liquid embolics (Onyx®) 
‐  
Implant positioned incorrectly 
with adequate sealing zone ‐ Coils* and liquid embolics (Onyx) with 
proximal covered stent extenders (iCAST) 
Implant positioned correctly with inadequate sealing zone ‐ Nellix Proximal Extenders with commercially 
available stent grafts in the visceral arteries (iCAST) (Secondary ChEVAS) 
Implant positioned incorrectly with inadequate sealing zone ‐ Nellix Proximal Extenders (NiNA with 
Polymer) 
‐ Nellix Proximal Extenders with commercially 
available stent grafts in the visceral arteries 
(iCAST) (Secondary ChEVAS) 
* See Appendix A on page 68  for a list of recommended coils 
 
8.6.1.2.  Type 1B Endoleaks  
A potential treatment option for Type 1B endoleak s have been identified, which can be used 
based on the physician’s preference: 
 Distal Covered Stents 
 
     The table below summarizes this options, aligning each with evaluation criteria:  
Implant and Anatomic 
Evaluation Criteria  Potential Treatment Options for Type IB Endoleaks 
Inadequate sealing in the between 
the Nellix Endobags and the iliac 
vessel wall ‐ Distal Covered Stent Extenders (Ovation iX 
Iliac Stent Graft) 
 
 
8.6.2.  Treatment Options for Migration 
The recommendation for treatment of migration is based on evaluation of the distance the 
implant has migrated, presence of endoleak and comparison between proximal and distal 
migration distances.  Based on evaluation of these factors, three potential treatment options for 
the treatment of migration have been identified: 
 CT Surveillance 
 Nellix proximal extenders with or without co mmercially available stent grafts in the 
visceral arteries (NiNA with polymer/ Secondary ChEVAS) 
 Nellix Stent Relining (NiNA without Polymer)  
o For subjects in which the proximal migration is more significant than the distal 
migration of the Nellix implant, stent relining should prevent or slow the rate of 
migration.  Relining the stent will incr ease the stiffness and column strength of 
the Nellix implant which may increase its resistance to the hemodynamic forces 
acting upon it. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
44 
 
 
  
The table below summarizes these options, a ligning each with evaluation criteria: 
 
Implant and Anatomic Evaluation 
Criteria  Potential Treatment Options for Migration 
Nellix implant has migrated <10mm, in 
the absence of Type 1A endoleak and a 
proximal seal zone of at least 10mm 
remains ‐ CT Surveillance (Enhanced Follow-
up) 
Nellix implant has migrated ≥10mm, in 
the absence of Type 1A endoleak and a proximal seal zone of at least 10mm 
remains ‐ Nellix Relining (NiNA without 
Polymer) 
Implant migration associated with Type 
1A endoleak and a proximal neck of at 
least 30mm is available ‐ Nellix Proximal Extenders (NiNA 
with Polymer)  
Implant migration associated with Type 
1A endoleak and a proximal neck of less 
than 30mm is available ‐ Nellix Proximal Extenders with 
commercially available stent grafts 
(iCAST) in the visceral arteries (Secondary ChEVAS) 
 
8.6.3.  Treatment Options for Aneurysm Expansion 
The recommendation for treatment of aneurysm expansion is based on the presence of Type 
1A/B endoleaks.  Based on evaluation of these factors, two potential treatment options for the treatment of aneurysm expansion have been identified: 
 Type 1A Endoleak Treatments 
 Distal Extension (Ovation iX Iliac Stent Graft) 
 
      The table below summarizes these opti ons, aligning each with evaluation criteria: 
Implant and Anatomic Evaluation 
Criteria  Potential Treatment Options for Aneurysm 
Expansion 
Aneurysm expansion is associated with 
Type 1A endoleak  Refer to treatment option for Type IA endoleak 
for further detail 
Aneurysm expansion is associated with Type 1B endoleak   ‐ Distal Covered Stent Extenders 
(Ovation iX Iliac Stent Graft) 
 
Aneurysm expansion in the absence of 
endoleak ‐ Distal Covered Stent Extenders 
(Ovation iX Iliac Stent Graft) 
 
 
  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
45 
 
 
  
8.7. PROTOCOL  DEVIATIONS 
 
A protocol deviation occurs when a clinical investigator and/or study site personnel do not 
conduct the study according to the clinical investig ational plan.  All deviations are recorded on 
a Protocol Deviation Form.  United States regulations (21 CFR 812.140) require that 
investigators maintain accurate, complete, and cu rrent records relating to the clinical study.  
This includes documents showing the dates and reasons for each deviation from the clinical 
investigational plan.  Depending upon the nature of the protocol deviation, expedited reporting 
and prior approval from Endologix may be require d.  All deviations will be summarized and 
submitted in IDE progress reports, annual repor ts, and the final study report to FDA. 
 
If Endologix finds that an investigator is not complying with the executed study 
agreements, the investigational plan, FDA regulations, or the requirements of the 
reviewing IRB, prompt action will be take n to secure compliance.  In addition, 
shipment of the device may be stopped or the participation of the investigator may be 
terminated. 
 
8.7.1.  Deviations with Exped ited Reporting Requirements 
 
For the following types of protocol deviations (per 21 CFR 812.150), an investigator 
is required to notify Endologix and the IRB within 5 business days of the deviation. 
 
• Emergency Deviation from the Investiga tional Plan (a deviation to protect 
the life or physical well-being of a subject in an emergency). 
• Failure to obtain Informed Consent  
 
 
Notification to Endologix and/or the IRB should be documented and maintained in 
the clinical study file at the site and at Endologix. 
8.7.2.  Deviations Requiring Prior Approval 
 
An investigator is required to obtain prio r approval from clinical study management 
at Endologix and the IRB before initiating de viations from the Investigational Plan 
that affect the scientific soundness of the plan, or the rights, safety, and welfare of 
the subjects (non-emergent situation).  Ho wever, prior approval is not required in 
situations where unforeseen circumstances ar e beyond the investigator’s control, 
e.g., subject did not attend scheduled follo w-up visit, laboratory test was performed 
incorrectly, and test equipment did not operate properly.  
8.7.3.  Non-Urgent Deviations 
 
Protocol deviations whic h do not have the urgency associated with expedited 
notification or prior Endologix/ IRB approva l (as discussed in the above paragraphs) 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
46 
 
 
 will be reported upon discovery, such as during completion of eCRFs or a 
monitoring visit.  
 
8.8. ADVERSE EVENT REPORTING  
Adverse events will be entered on the appli cable eCRF and in the patient’s medical 
records. The date of onset, severity, and ac tion taken are requested to be identified 
by the PI. 
8.8.1.  General Definitions 
An adverse event (AE) is any undesirable c linical occurrence in a patient enrolled in 
the trial that does not necessarily have a cau sal relationship with the treatment. An 
AE can therefore be any unintended sign, symptom or disease temporally associated 
with the use of an investigational product,  whether or not related to the use of the 
product. 
 
A serious adverse event (SAE) is an adverse event that: 
• Led to a death. 
• Led to a serious deterioration in the health of the subject that: 
a. Resulted in life threatening illness or injury. 
b. Resulted in a permanent impairment of a body structure or a body function. 
c. Required in-patient hospitalization or prolongation of existing hospitalization. 
• Resulted in medical or surgical endov ascular procedure to prevent permanent 
impairment to a body structure or a body function. 
• Led to fetal distress, fetal death, or a congenital abnormality or birth defect. 
An unanticipated adverse device effect (UADE) is any serious adverse effect on health or safety 
or any life threatening problem or death caused by or associated with a device, if that effect, 
problem, or death was not previously identified in nature, severity, degree of incidence. 
Additionally, an unanticipated adverse device e ffect includes any other unanticipated serious 
problem associated with a device that relates to  the rights, safety, or welfare of subjects. 
Severity of an AE is a clinical determination of the event intensity. The severity assessment for 
a clinical AE should be completed using the following definitions as guidelines: 
Mild (+1): Awareness of sign or symptom, but easily tolerated. 
Moderate (+2): Discomfort enough to cause interference with usual activity. 
Severe (+3): Incapacitating with inab ility to work or do usual activity. 
NOTE: An event that is fatal shou ld be recorded as death on the ADVERSE EVENT  eCRF. The 
cause of death will be detailed on the Serious Adverse Events  section of the form. 
A relationship to device or procedure of an AE is  a judgment determination made by the PI that 
there is a logical connection between device u se (e.g., delivery system manipulation) and the 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
47 
 
 
 occurrence of the AE.  
8.8.2.  Reporting of Adverse Events 
For all adverse events occurring during the study period, data must be entered in the Adverse 
Event eCRF in the EDC system.  For serious a dverse events (SAEs), the section of the eCRF 
describing the serious nature of the AE must also be completed. 
All device and procedure related adverse ev ents will be investigated by Endologix. 
The PI should supply to Endologix and the res ponsible EC/IRB with a complete, written case 
history (AE forms) and any additional redacted  source documentation a nd information (e.g., 
other diagnostic testing, discharge reports , autopsy reports, etc.) as it is available. 
Deaths 
For any death, regardless of cause or timing, it is recommended that the site notify the 
Endologix Clinical Department via the EDC system within 1 working day of awareness . 
The PI should supply to Endologix and the r esponsible EC/IRB with a complete, written case 
history (AE forms) and any additional redacted  source documentation and information (e.g., 
other diagnostic testing, discharge reports, autopsy reports, etc.).   
In all cases, the death certificate is to be uploaded to the EDC system. Every attempt should be 
made to obtain as much detailed information on the events or conditions leading up to the death 
as possible. If the patient was hospitalized, a co py of the discharge summary source document 
is required. Also sites can search Social Security Death Index (SSDI) or CDC National Death 
Index (NDI) to obtain more information. 
If approval is obtained from the patient or a patient ’s authorized family member, the site should 
notify Endologix for submission of the explant to Endologix. A device explant kit will be 
provided to the hospital for processing and ship ment to an independent pathologist per 
established methods. To request a kit, send a fax to Endologix at +1 949-954-7601, or contact 
Endologix by telephone at +1 (949) 595-7200. 
8.8.3.  Adverse Events: require d reporting timeframes 
Note: Site reporting times to Endologix only; responsible IRB/EC reporting requirements must 
still be followed by the site, in addition to those recommended below. 
AE Type Reporting Recommendations 
Non-device or procedure related AE Recommended monthly at minimum 
Device or procedure related AE Within 10 working days 
Non-device or procedure related SAE Within 10 working days 
Device or Procedure related SAE Within 1 working day 
Death as outcome (regardless of cause) Within 1 working day 
Unanticipated Adverse Device Effect Within 1 working day 
8.8.4.  Secondary procedures  
For subjects that experience any non-diagnostic i nvasive secondary treatment of the groin access 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
48 
 
 
 areas or of the abdominal aortoiliac vessels (e.g ., hematoma drainage, vascular exploration for 
bleeding, iliac stenting, thrombectomy, additional device placement for endoleak, embolization 
for Type II endoleak, conversion to open repair, etc.), it is important to identify the specific 
procedure performed on the relevant ADVERSE EVENT  eCRF. A copy of the discharge summary 
source document should be uploaded to the EDC system. 
8.8.5.  Anticipated Adverse Events 
Adverse events that could potentially occur du ring this investigation are called anticipated 
adverse events.  These events must be reported if clinically significant.  A list of anticipated AEs 
are listed in alphabetical order: 
 Access site complications and sequelae (e.g ., dehiscence, infection, pain, hematoma, 
pseudoaneurysm) 
 Allergic reaction to contrast agent (e.g., pr uritus, urticaria, bronchospasm, angioedema, 
hypotension or anaphylaxis that occurs during or post-procedure) 
 Amputation 
 Anesthetic complications and sequelae (e.g., aspiration) 
 Aneurysm enlargement 
 Aneurysm rupture  
 Arterial damage or trauma (e.g., bleed ing, perforation, dissection, rupture) 
 Arterial or venous thrombos is and/or pseudoaneurysm 
 Arteriovenous fistula 
 Bleeding requiring transfusion and/or surgical intervention 
 Bowel complications (e.g., ileus, ischemia, infarction, necrosis) 
 Cardiac complications and sequelae (e.g., a rrhythmia, myocardial infarction, congestive 
heart failure, hypotension, hypertension) 
 Catheter or implant component fragmentation and sequelae (e.g., embolization, vessel 
trauma) 
 Claudication  
 Coagulopathy 
 Death (due to any cause) 
 Edema 
 Embolization (micro and macro) with transi ent or permanent ischemia or infarction 
 Endoleak  
 Fever and localized inflammation 
 Genitourinary complications and sequelae (e.g., ischemia, fistula, incontinence, hematuria, 
impotence, infection) 
 Hepatic failure 
 Infection of the aneurysm, device access site , including abscess formation, transient fever 
and pain. 
 Local or systemic neurologic complications and sequelae, transient or permanent (e.g., 
stroke, transient ischemic attack, parapleg ia, paraparesis, paralysis, numbness and/or 
tingling in legs) 
 Lymphatic complications and sequelae (e.g., lymph fistula) 
 Nellix implant: improper component placeme nt; incomplete component deployment; 
component migration; occlusion/thrombosis; in fection; stent fracture; EndoBag material 
wear; dilatation; erosion; p uncture and perigraft flow 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
49 
 
 
  Thrombosis or occlusion of stent graft or  arterial vessel of the lower extremities 
 Pulmonary/respiratory complications and sequelae (e.g., pneumonia, respiratory failure, 
prolonged intubation, pulmonary embolism) 
 Renal complications and sequelae (e.g., artery occlusion, infarction, insufficiency, failure) 
 Secondary Intervention  
 Surgical conversion to open repair 
 
8.8.6.  Unanticipated Adverse Device Effect 
The investigator shall submit to Endologix and to the reviewing EC/IRB a report of any 
unanticipated adverse device effect occurring durin g an investigation as soon as possible, but in 
no event later than 24 hours after the PI first lear ns of the effect. PIs must submit to Endologix 
documentation of the report made to the EC/IRB via  the EDC system.  Endologix will report a 
UADE to the FDA within 5 working days of becoming aware of the event, as required by 
regulations. 
8.8.7.  Adverse Event Definitions 
The following event definitions will be applied during this study.  
 Death : Any death occurring during the stud y period, regardless of cause. 
o Aneurysm-related death is defined as any death occurring within 30 days from the date 
of the procedure, regardless of cause, and d eath due to aneurysm rupture or following 
any procedure intended to treat the aneurysm.  
o Cardiac-related death  is defined as death due to arrh ythmia, heart failure (including 
cardiogenic shock), or myocardial infarction. 
o Pulmonary-related death  is defined as death due to due to pulmonary edema, respiratory 
failure, or pulmonary embolism. 
o Vascular-related death  is defined as death due to stroke, cerebral hemorrhage, or other 
clear vascular event that is not categorized as cardiac-related or pulmonary-related. 
o Other  is to be used to identify a death due to  any event that cannot be clearly categorized 
as above, but where some information is available. 
o Unknown  is to be used to identify a deat h where no information is available. 
 Procedural Technical Failure  is defined as a failure of the Nellix system to be delivered 
and deployed, such that the procedure is not completed, or the device failure results in a 
serious complication, or a residual endoleak occurs that cannot be resolved during the index procedure and is still present at the 30 day CT as read by the Core Lab. 
 Major Adverse Event : An event occurring during the study that meets one of the following 
criteria: 
o All-Cause Death  (see above);  
o Bowel Ischemia : the lack of adequate blood flow  to the intestines that requires 
intensification of medical therapy or surgical/endovascular intervention; 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
50 
 
 
 o Myocardial Infarction : the presence of raised levels of one or more cardiac biomarkers 
in comparison to local labo ratory reference ranges;  
o Paraplegia : Paralysis of the lower extremities inclusive of the lower trunk;  
o Renal Failure : the need for temporary or permanent dialysis or >0.5mg/dL increase in 
pre-operative serum creatinine level at two consecutive intervals; 
o Respiratory Failure : pneumonia or respiratory failure requiring ventilator support 
beyond 24 hours post-procedure; 
o Stroke : a sudden development of neurological deficit due to vascular lesions of the brain 
such as hemorrhage, embolism, or thro mbosis that persists for >24 hours; 
o Procedural Blood Loss >1,000mL : Estimated blood loss during the index procedure 
≥1,000mL. 
 Other Definitions: 
o Aneurysm Sac Enlargement : Aneurysm sac diameter increase of >5mm in late follow-up 
as compared to the initial po st-operative measurement. 
o Aneurysm Rupture : bleeding or leaking of blood from the aneurysm subsequent to the 
index procedure. 
o Clinically significant migration : Core Lab reported stent distal movement >10mm from 
the original implant location relative to the cen ter of the distal renal artery resulting in 
an intervention or in a serious complication. 
o Conversion to Open Repair : open surgical repair of the abdominal aortic aneurysm  due 
to unsuccessful delivery or deployment of the stent graft, due to complications or other 
clinical situations that precluded successful  endovascular treatment, or at any time 
following initial successful endovascular treatment for any reason. 
o Device Positional Stability : Core Lab reported position of each stent relative to the center 
of the L3 vertebrae. Stable positioning is defined as within 5mm of the positioning on 
the first post-operative CT scan. 
o Luminal Thrombus Requiring Intervention : any endovascular surgical intervention after 
completion of the Nellix System implantati on for resolution of endograft thrombosis. 
o Distal Ischemia : New onset of compromised peripheral blood flow resulting in femoral 
or peripheral arterial occlusion or stenosis (attributable to the index procedure and not 
related to natural progression of atherosclerotic  disease) causing a threat to the viability 
of the limb and requiring surgical or percutan eous intervention; or stent graft occlusion 
requiring any intervention.. 
o Endoleak : Clear evidence of contrast outside of one or both EndoBags which 
communicates with the aneurysm sac origina ting proximally at the infrarenal segment 
(Type IA), distally (Type IB); between components, if an extender is used (Type III); trans-device (Type IV); or from a patent collateral vessel (Type II: e.g., lumbar artery; 
inferior mesenteric artery). Contrast outside of an EndoBag that does not communicate 
with the aneurysm sac is not to be reported as an endoleak. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
51 
 
 
 o Migration : Core Lab reported stent distal movement >5mm from the original implant 
location relative to the center of the distal renal artery.  
o Clinically significant migration: Core Lab reported stent distal movement >10mm from 
the original implant location relative to the cen ter of the distal renal artery resulting in 
an intervention or in a serious complication. 
o Occlusion : Intervention for stent occlusion or as reported by the Core Lab. 
o Secondary procedure : any non-diagnostic intervention after the index procedure 
intended to correct or repair an endoleak, device occlusion, migration, aneurysm sac 
expansion and/or a device defect (including infection). 
 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
52 
 
 
 9. RISK ANALYSIS 
The decision to repair an aortic aneurysm is generally based on the risk of rupture, the risk of complications 
of surgery, and patient preference. There are currently  two methods used to repair aortic aneurysms. The 
conventional method is an open surgi cal repair, with the implantation of  a synthetic graft to replace the 
diseased aneurysmal vessel through a large abdominal incision. More recent technological developments 
have resulted in an alternative, minimally invasive, endovascular aneurysm repair, in which a prosthesis is 
placed within the aorta through a small incision in the groin. Blood can then flow through the implanted 
device and is excluded from the aneurysmal portion of the aorta. 
The disadvantages of open surgical repair are: general an esthesia is required, it is a major abdominal surgery 
(large incision), has a significant surgical complicatio n rate, and typically requires a long hospital stay and 
recovery. EVAR/EVAS enables local or regional anesth esia to be used, uses a minimally invasive groin 
incision for catheter-based access, and has been reporte d in multiple studies to offer a lower perioperative 
complication rate, reduced blood loss and procedure tim es, and shorter hospital stay. In contrast to open 
repair, EVAR/EVAS is a relatively new treatment, long term results have not been fully established, and 
life-long surveillance is recommended to verify impl ant integrity and patency and continued aneurysm 
exclusion. Multiple device systems are CE Marked  and marketed in the European Community for 
endovascular abdominal aortic aneurysm repair. All of these devices require the introduction of catheter-
based treatment devices varying in outer diameter pr ofile. Standard vascular exposure is indicated for 
access. Prospective clinical study results support the safety and effectiveness of these devices through early 
follow-up (to 30 days) and for some in late follow-up to one year and beyond to up to five years.  
As with any procedure there are risks of serious comp lications, such as death. The inclusion and exclusion 
criteria for this population have been carefully establis hed to limit the risk of mortality and morbidity in 
this population. The overall risk will be evaluated on an individual b asis and discussed with each patient. 
All of the potential adverse even ts outlined previously could cau se prolonged illness, permanent 
impairment of daily functi on or, in rare cases, death. Possible treatments could include, but are not limited 
to, emergency cardiac or vascular surgery.   
Eligibility criteria that exclude subjects who are at higher risk for experiencing an anticipated adverse 
event have been selected to reduce th e potential risks to subjects who partic ipate in this study. In addition, 
the assessment of patient computed tomography angi ography imaging by an experienced Core Laboratory 
is also intended to reduce the potential risks to subjects who participate in this study. 
Pre-procedural high resolution, contrast-enhanced CT scanning and intraprocedur al arteriography will be 
used to identify and target the aor tic anatomy to facilitate the proper in troduction, delivery, and deployment 
of the endovascular repair devices. Physician experience, rigorous app lication of a common protocol, and 
careful performance of the procedure with close monitori ng of the patient after the procedure will also help 
to minimize risks. 
The alternative to endovascular repair  of AAA is open surgical repair. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
53 
 
 
 10. STATISTICAL PROCEDURES 
10.1 ANALYSIS POPULATIONS  
All primary analyses will be conducted on an intentio n to treat (ITT) basis. Whereas ITT is a concept 
intended to be applied to randomized  trials, its use in this analysis will imply that subjects will be 
analyzed based on the attempt to implant trial devi ces during the procedure.  Subjects who complete 
the trial through 12 month follow-up, or have expired prior to 12 month follow-up, will comprise the 
Completed Cases (CC) population. Additional anal yses will be conducted in the CC population. 
Completed Cases subjects who have an implanted device and are alive upon exit from the procedure 
room will be considered per protocol (PP) population.  All roll-in subjects treated will be evaluated as 
a separate feasibility group.  
10.2 PATIENT ACCOUNTABILITY AND MISSING DATA 
The proportion of subjects with documented follow-up at each interval will be presented descriptively. 
The number of diagnostic, laboratory, and clinical ev aluations will be tabulated by follow-up interval. 
Also, a listing of patients who initially consent but do  not undergo a procedure due to withdrawal of 
consent prior to procedure will be given. However, these subjects will not  be included in any analysis.  
Information on missing or withdrawn subjects will be tabulated presenting the number and proportion 
of subjects eligible for and compliant with each follow-up examination.  Subjects who withdraw from 
the trial will be tabulated with the reasons for th e withdrawal. Additional sensitivity analyses will be 
performed as described below. 
The evaluation of subjects with missing data presents a special concern in ITT analyses. All clinical 
studies analyze the results based on the completed ca ses (i.e., those who complete the trial).  Because 
missing subjects do not have final data, they present a problem for ITT analyses. The statistical 
community recommends that multiple sensitivity analy ses be conducted to determine the robustness of 
the result in subjects who complete the study.*,†,‡,§  The intention of these analyses is to demonstrate 
that the results obtained from the evaluable subjects are not biased. 
As a result, sensitivity analyses using multiple imputa tions will be conducted to evaluate the robustness 
of the study result accounting for missing observa tions. The primary effectiveness endpoint analyses 
will be recalculated using an unbiased imputation of the determination of success or failure.  It is 
expected that the number of subjects with missing e ffectiveness data at one year will be approximately 
10% of study enrollment. The first method of imput ation will be to assign values using a simple random 
sample from the subjects with outcomes at one year.  This system is denoted the “Hot Deck by Simple 
Random Sampling with Replacement”.** The number of subjects to impute is small and trying to 
                                                      
*Pocock S. (1983). Clinical Tr ials (A Practical A pproach). John Wiley an d Sons, Chichester. 
†Friedman L, Furberg C, and DeMets D.  Fundamentals of Clinical Trials .  1985: Mosby Year Book, St. Louis. 
‡Guidance for Industry: E9 Statistical Princi ples for Clinical Trials. U. S. Departme nt of Health and Human Services, Food and 
Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research.  International 
Committee on Harmonizati on, September 1998. 
§Rubin D.  Multiple Imputation for Nonresponse in Surveys. 1987: John Wiley and Sons, New York . 
**Little R and Rubin D. Statistical Analysis with Missing Data. 2002. John Wiley and Sons, New York. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
54 
 
 
 provide a more sophisticated imputation met hod would require modeling missingness with only 
approximately 10% of enrolling subjects or less with  missing data.  Additional sensitivity analyses will 
be done by using other imputation methods; Last Ob servation Carried Forward (LOCF); subjects lost 
to follow-up considered an endpoint failure; impute the missing result as having succeeded the 
endpoint; and impute the missing value by a generating a random number and comparing it to the value 
of the performance goal for effectiveness. 
A comparison of baseline characteristics of the subj ects with missing data and those without missing 
data will be done to determine if there is evidence th at the data are not missing at random (it is not 
possible to determine that data are missing at random). If the missing at random assumption is clearly 
violated by these comparisons, it is usually possible to find a sub-group that are not missing at random 
who have to be imputed differently, such as assigning the worst score to subjects in the sub-group.  For 
example, the proportion of subjects missing an outcome may be much greater at a given study site 
which may also have a higher rate of failure.  T hose subjects from that site may be assigned a failure 
and the baseline comparisons of the remaining subjec ts will be rechecked to see if the imbalances are 
resolved. If this resolves the missing at random di fficulty, the sub groups will be given special scores 
and the remaining subjects will be imputed as describ ed above.  The resolution of the imbalance will 
be retested by the same methods with th e subjects identified above removed.   
The primary imputation will be done 10 times with 10 different seeds to initiate the random selection 
and the combined P-value for the 10 imputations will be obtained by a method described in Rubin (1987) and in the SAS manual for PROC MIANALYZE.  The seeds to be used for the 10 imputations 
are selected from a pseudo-random number table in Steele and Torrie (1960) and are 70303, 18191, 
62404, 26558, 92804, 15415, 02865, 52449, 78509, and 43896.
* 
With regard to imputation for the primary safety endpo int, that endpoint is obtained so close to the 
procedure that there will be very little missing data.  If any of the test subjects are lost to follow-up 
prior to 30 days, that patient will be assigned an MAE for primary analysis purposes.  
In addition to the above missing data analyses, Ti pping Point analyses will also be performed.  For 
each imputed data set, one MAE will be added and th e exact binomial test will be done.  The number 
of steps required to achieve non-significance of the MAE endpoint will be reported for each 
imputation.  The supportive tipping point analysis will be repeated for the completed cases and will 
be done in the same way by adding one MAE and doi ng an exact binomial test of the result.  The 
number of steps required to achieve non-significan ce will be reported for this analysis as well. 
 
10.3 GENERAL NOTES  
Analyses of MAEs and other adverse events will be conducted at exact time points. Early events are 
defined as those occurring from the date of the proc edure to 30 calendar days post-operatively. Late 
events are defined as those occurring from after 30 calendar days post-operatively (from day 31 
forward). Events within six months and one year, respectively, are those occurring up to and including 
                                                      
*Steele R and Torrie J. Principles and Procedur es of Statistics. 1960 . McGraw-Hill, New York. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
55 
 
 
 180 days and 365 days following the procedure. 
For categorical variables, summary statistics will in clude counts and proportions. Confidence limits for 
proportions will generally be given; for binary variables the confiden ce limits will be computed using 
the exact binomial distribution. Supportive multiv ariate analyses of stratified comparisons of 
categorical variables will be performed usi ng appropriate logistic or Cox regression. 
For continuous variables, summary statistics will in clude means, standard deviations, medians, and 
range. Groups will be compared using t-tests or analysis of variance, or Kruskal-Wallis tests will be 
used to compare more than two groups (such as tria l sites). When multiple comparisons are performed 
after ANOVA, Scheffé’s method will be used. Th e exact Wilcoxon test will be used to compare 
continuous variables where severe departures from normality are observed. 
For ordinal variables, comparisons will be perform ed using the exact Wilcoxon rank-sum test. Unless 
otherwise specified, the exact form of each algorithm will be the default of SAS Version 9.1 or later. 
Some preliminary descriptive analyses may be done  with other software tools to be specified. 
10.4 BASELINE COMPARABILITY ANALYSIS  
A set of important demographic or prognostic variables will be compared across study sites to 
determine homogeneity of sites in terms of baselin e patient characteristics. Factors found to differ 
significantly by site will identify that variable or s ite as a possible covariate in subsequent analyses.  
In the analysis of comparability of trial sites, it is  anticipated that a small number of sites may have a 
patient enrollment that is too small to allow meani ngful statistical analysis. To allow the inclusion of 
sites with this condition, small sites will be comb ined into one pseudo-site the size of which will not 
exceed the size of the largest trial site. It is not  possible to determine the number of subjects below 
which this aggregation will occur until after enrollment is completed, but generally trial sites with four 
or fewer subjects may be combined. 
10.5 POOLING  
Data pooling incorporates two factors: combination of data across sites and the actual method of 
obtaining an estimate of the endpoint from combined  data. Data will be combined from multiple study 
sites for the study analyses. The justification for th is pooling is made on a clinical basis with three 
critical factors: The basis for pooling comes from : 1) The study sites must implement one common 
protocol; 2) The sponsor must ensure consistent application of study procedures and compliance with 
the protocol; and, 3) the study sites must use common data collection procedures.*   
In order to determine if there is a similar respon se across the study sites for each response, the primary 
safety and effectiveness will be tested for homogeneity by extension of the Fisher’s exact test (Fisher-
Freeman-Halton).. If the P-value for study site is l ess than 0.15 for any resp onse, differences between 
study site will be assumed to exist and the overall es timate of the proportion in the test subjects will be 
obtained by taking a weighted average of the proportions  at each site with the weight being the inverse 
                                                      
*Meinert C. Clinical Trials: Design , Conduct, and Analysis. 1986; Oxford University Press. New York, NY 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
56 
 
 
 of the variance of the proportion at that site.* The sum of these weighted proportions divided by the 
sum of the weights will be the overall estimate for th e study. Both the safety and effectivness measures 
will employ weighted proportions as the basis for the st atistical test.  The test of significance in these 
circumstances are fully described below in Sections 10.6 and 10.7. 
If the heterogeneity P-value is less than 0.15, an an alysis of the primary effectiveness endpoint by the 
Fleiss (1993) method will be done. The estimates obtai ned from this method provide a mechanism to 
test homogeneity and to adjust the value of the overall estimate if heterogeneity exists. 
10.6 PRIMARY SAFETY ANALYSIS  
10.6.1  Primary Safety Hypothesis 
The primary safety hypothesis to be tested is that  the rate of Major Adverse Events (MAEs) at 
30 days in the study population is less than 56%, which is the rate of MAE at 30 days in the 
Society for Vascular Surgery (SVS) open surgery group. MAEs include all-cause death, bowel 
ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, stroke, and 
procedural blood loss ≥1,000mL. The hypothesis test will be evaluated by the exact test as a 
one-tailed test, using significance level α=0.025. Multivariable analyses will be used to assess 
predictors of success. The null and alte rnative hypotheses are provided below.  
H0: Pt ≥ 0.56  vs.  H 1: Pt < 0.56, 
where P t is the MAE rate at 30 days in the study test group. 
 
10.6.2  Sample Size 
The primary trial safety variable is the rate of MAEs (as defined previously) at 30 days following 
treatment with the Nellix System. The SVS open surgical group has been characterized.†  
Owing to the availability of data within the SVS da tabase for this surgical group, it is reasonable 
to consider it for sample size generation for the safety endpoint. The MAE rate in the SVS 
surgical control group at 30 days is 56%. This  is reasonably conservative as a performance goal. 
To this point, a recent publication finds that th e rates of these major adverse events are similar 
between open infrarenal aneurysm repair and ope n repair of juxtarenal aneurysms and those 
involving the renal arteries), with the excep tion of bleeding and renal events, which were 
significantly higher with open more complex aneurysm repair.‡ To be further conservative and 
to account for the fact that in the present stud y, shorter necked infrarenal aneurysms will be 
treated endovascularly with the Nellix System, the rate for the test arm has been increased to 
16.6%. It is expected that the rate of MAEs within  30 days in in this study will be smaller than 
                                                      
*Fleiss, J. The statistical basis of meta-analysis. Statistical Methods in Medical Research 1993;2:121-45. 
†Zwolak RM, Sidawy AN, Greenberg RK, et al. Lifeline registry of endovascular aneurysm repair: open repair surgical controls in 
clinical trials. J Vasc Surg 2008;48:511-8.  The SVS surgical control group results are de tailed in the FDA Summary of Safety and 
Effectiveness Data (SSED) for the Medtronic Talent™ Device.  
‡Jeyabalan G, Park T, Rhee RY, et al. Comparison of modern open infrarenal and pararenal abdominal aortic aneurysm 
repair on early outcomes and renal dysfunction at one year. J Vasc Surg 2011;54:654-9. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
57 
 
 
 that of the SVS historical surgical control grou p as noted above. The sample size for this trial is 
calculated to demonstrate a difference between  the observed MAE rate and the performance 
goal established using SVS historical surgical data. 
If we assume that P t = 0.166, P c = 0.560, one-sided alpha = 0.025, and power = 80%, a very 
small number of subjects are required in the treatment group to test the above hypothesis.  Should 
the Nellix rate be as high as 31%, then 50 subj ects would provide approximately 81% power to 
test the primary safety endpoint at the one-sided 2.5% significance level.   
10.6.3  Analysis Plan 
All subjects who receive treatment will be included in the safety analysis.  
A univariate test will be done with the exact bi nomial distribution to determine if the frequency 
of MAE in the  study population is statistically significantly less than 0.56. The formula for this 
test is provided below. 
 025.0 44.056.0 )56.0 (
1



t
tx
kkn k t
tknxXP  
Where x t is the number of study subjects experiencing an MAE and n t is the number of subjects 
in the study. If the above expression holds for the observed x t, the null hypothesis will be rejected 
and the alternative hypothesis will be accepted. 
If there is heterogeneity among the study sites in  MAE response, the analysis will be done by 
the method of Fleiss (1993). The test statistic will be given by the following formula. 
 
TT
pSEpz56.0   
 
Where the formula for the weighted estimate of the proportion is given by the following: 
 


kkkTkk
TWpW
p
   
And the formula for the weight in site k is given by the following: 
 
 1
11



 k k
kk p pnW  
 
And the formula for the standard error is given by the following: 
 2/1
1



Tm
kTk T W pSE  
If the z has a P-value less than a one-sided alpha  of 0.025, the null hypothesis will be rejected 
and the alternative will be accepted. 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
58 
 
 
 To determine those factors that may be associat ed with MAE, a supportive covariate analyses 
will be performed by logistic regression to determ ine if there are differences in the rates among 
groups when adjusted for other factors in th e  study population only. Covariates for these 
analyses will be age, gender, ASA class, cardiac/co ronary artery disease (a composite variable 
to include arrhythmia, CHF, prior MI, CABG/PCI, heart valve repair/replacement), histories of 
cancer, cerebrovascular accident, coagulopathy, COPD, diabetes, hypertension, liver disease, 
peripheral arterial occlusive disease, renal fa ilure, smoking, maximum aneurysm diameter, and 
study site. The final model will be reduced by backward elimination until no covariate terms 
remain in the model with a P-value less than 0.05. 
A descriptive analysis and a Kapl an-Meier analysis of the MAE composite at 30 days will be 
presented. The descriptive analysis will present the rates for the composite MAEs and each 
individual adverse event that is part of the composite with corresponding 95% exact confidence 
intervals. 
 
10.7 PRIMARY EFFECTIVENESS ANALYSIS  
10.7.1  Primary Effectiveness Hypothesis 
The primary effectiveness hypothesis is that th e Treatment Success rate at one year exceeds a 
performance goal of 80%. The hypothesis test will be evaluated using the exact binomial 
distribution as a one-tailed test, using significance level α=0.05. Multivariable analyses will be 
used to assess predictors of success. The null a nd alternative hypothesis is presented below.  
H0: P ≤ 0.80 vs. H 1: P > 0.80 
Where P is the rate of Treatmen t Success as defined in §10.7.2. 
 
10.7.2  Sample Size 
The primary trial effectiveness variable is the Treatment Success rate at one year post-
operatively. Treatment Success is a composite of clinically-relevant outcomes, including 
procedural technical success and freedom from: aneurysm rupture; conversion to open repair; 
Type I endoleak at 12 months; Type III endoleak at 12 months; clinically significant migration; 
aneurysm sac enlargement; or secondary endovascula r procedure up to 12 months for resolution 
of Type I or III endoleak, device occlusion, migra tion, aneurysm sac expansion and/or a device 
defect.  
The sample size is obtained by using the exact binomial distribution using PASS 2008. A sample 
size of 132 subjects at one year in the study population will have 80% power against a null performance goal of 80% if the proportion of Treatment Success is 88% or higher. It is estimated 
that the rate of Treatment Success will be greater than 88%. 
It is anticipated that the drop-out rate of the tr ial will be 12% or less. Because the larger of the 
two sample sizes after adjustment for loss to wit hdrawal is the one for effectiveness, a minimum 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
59 
 
 
 of 132/0.88 = 150 subjects will need to be recruited for this study. Thus to allow for deviations 
from assumptions, 150 subjects will need to be recruited for this study.   
10.7.3  Analysis Plan 
The primary effectiveness analysis  will compare the Treatment Success  rate as defined 
previously to a target rate of 80%. The nu ll and alternative hypoth eses are defined below. 
 
H0: Pt ≤ 0.80 
 H
1: Pt > 0.80 
 
Where P t = the proportion of treated subjects who meet the Treatment Success definition.  The 
observed proportion of subjects with Treatment Success at one year post-procedure will be 
tested with the exact binomial distribution under the null hypothesis given in the inequality above. The formula for this expression is presented below. 
 
05.0 20.080.0 )80.0 ( 



t
ttn
xkkn k t
tknxXP  
 
Where x t is the number of successes at one year and n t is the number evaluated.  If the one-
sided P-value is less than 0.05, the null hypoth esis will be rejected and the study hypothesis 
will be demonstrated. 
If the study site success proportions across study site are not homogeneous, then the method of 
Fleiss described above will be used in the Test  arm only to obtain a weighted estimate of the 
proportion successful.  The mean proportion is foun d the same way as the first equation above. 
The test statistic becomes a z-statistic with the following formula:  
 
 
TT
pSEpz80.0   
 
Where the formula for the weighted estimate of the proportion is given by the following: 
 

kkkTkk
TWpW
p  
And the formula for the weight in site k is given by the following: 
 
 1
11



 k k
kk p pnW  
 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
60 
 
 
 And the formula for the standard error is given by the following: 
 
 2/1
1



Tm
kTk T W pSE  
 
If the z < 1.645 (P=0.05, one-sided), then the nu ll hypothesis will be rejected in favor of the 
alternative and the primary effectiv eness endpoint will be achieved.  
To determine those factors that may be associ ated with Treatment Success, covariate analyses 
will be performed by logistic re gression to determine if there are differences in the Treatment 
Success rates in the study population when adjusted for other factors. Possible covariates eligible 
for these analyses will be age, gender, ASA class, cardiac/coronary artery disease (a composite 
variable to include arrhythmia, CHF, prior MI , CABG/PCI, heart valve repair/replacement), 
cancer, cerebrovascular accident, COPD, diabet es, hypertension, liver disease, peripheral 
arterial occlusive disease, renal failure, smoking, maximum aneurysm diameter, and study site. 
Because there are too many possible covariates to  include in a model, screening is necessary to 
reduce the number of eligible covariates for consid eration in the final model. Screening logistic 
regression models to include only the covariate, will be used. If the P-value for the screening 
model for the covariate is less than 0.20, the co variate will be included in the competition for 
the final model. The final model will be obtaine d by manual backward elimination to have the 
seven or fewer covariates with P-value less than 0.05.   
 
10.8 ADDITIONAL EVALUATIONS  
 Procedural and In-Hospital Evaluations : The estimated blood loss volume, % of subjects 
receiving a blood transfusion, contrast volume, fluoroscopy time, endovascular device time, Polymer volume used, procedure time , anesthesia time and type, frequency of 
concomitant procedures, ICU time, time to hospital discharge, and % of subjects 
discharged to skilled nursing facilities or assi sted living facilities who were not prior 
residents will be presented descriptively. Qua litative variables will be presented with rate. 
Quantitative variables will be presented with mean, standard deviation, median, minimum 
and maximum. 
 
Mortality : The proportion of subjects with mortality (all-cause and aneurysm-related) will 
be presented at 30 days and at each subsequent time point for which data are available 
(i.e., six months, and annually at years 1 thr ough 5). A descriptive analysis and a Kaplan-
Meier analysis of all-cause and aneurysm-rela ted mortality through 30 days and for late 
follow-up including 30 days will be presented.  
 Major Adverse Events (MAE) Individual Components : The proportion of subjects 
experiencing each category of MAE within 30 days and after 30 days at each subsequent 
time point for which data are available will be presented.  
 Composite Late MAEs (after 30 days) : The proportion of subjects experiencing an MAE 
after 30 days will be presented at each subseque nt time point for which data are available. 
A descriptive analysis and a Kaplan-Meier analysis of the MAE composite will be 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
61 
 
 
 presented for follow-up through 30 days and for late follow-up including 30 days. The 
descriptive analysis will present the rates for the composite MAE and each individual 
adverse event that is part of the composite. 
 Aneurysm Rupture : The proportion of subjects experiencing a rupture of the aneurysm will 
be presented at 30 days and at each subsequent  time point for which data are available.  
 Conversion to Open Repair : The proportion of subjects undergoing surgical conversion to 
open repair will be presented at 30 days and at  each subsequent time point for which data 
are available.  
 Serious Adverse Events (SAEs) : The proportion of subjects experiencing an SAE will be 
presented descriptively by time point.  
 Non-serious AEs : The proportion of subjects experi encing a non-serious AE will be 
presented descriptively by time point.  
 Device Performance : A descriptive analysis of the following will be done based on Core 
Lab evaluations at 30 days and at each subseque nt time point for which data are available. 
A determination will be made from the data as to whether any observation was associated 
with an SAE or device malfunction. 
 Luminal Thrombus Requiring Intervention : any endovascular surgical intervention after 
completion of the Nellix System implant for resolution of endograft thrombosis . 
 Aneurysm Sac Changes : The changes in aneurysm sac (vessel) diameter from the first 
post-operative CT evaluation will be presen ted at each subsequent follow-up. The 
maximum diameter parameter will be used fo r the analysis because it is the basis for 
comparison to other studies with endografts. For each follow-up interval, the number and percent of subjects with increased sac diameter (>5mm), stable sac diameter ( ≤5mm), or 
decreased sac diameter (>5mm) will be presented.  
 Incidence of Migration : Core Lab reported stent distal movement >5mm from the original 
implant location relative to the cen ter of the distal renal artery. 
 Incidence of Clinically Significant Migration : Core Lab reported stent distal movement 
>10mm from the original implant location relative to the center of the distal renal artery resulting in 
an intervention or in a serious complication.  
 Incidence of Endoleak : The occurrence of endoleak (any type or location, new and 
persistent) will be presented descriptively at each follow-up.  
 Incidence of Stent Occlusion : The occurrence of stent occlusion will be presented 
descriptively at each follow-up. Renal Functi on Evaluations: A descriptive analysis of 
renal function will be done based on serum cr eatinine levels and calculated estimated 
glomerular filtration rate (eGFR) at 30 days  and at each subsequent timepoint for which 
data are available. Renal dysfunction will be defined as a reduction in eGFR of >30% 
from the preoperative value.  
 Nellix Implant Patency and Integrity : A descriptive analysis of stent patent luminal flow, 
absence of stent fracture, kinking, or occlus ion, and absence of device failure will be 
determined by contrast-enhanced CT scan, as assessed by the independent core laboratory 
at 30 days and at each subsequent time point fo r which data are available. A determination 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
62 
 
 
 will be made from the data as to whether th e occurrence was associated with an SAE or 
device malfunction. 
 Secondary Endovascular procedures : A descriptive analysis of secondary endovascular 
procedures for resolution of endoleak (Type I or III), device occlusion, migration, 
aneurysm sac expansion, and/or a device def ect (including infection) will be done at 30 
days and at each subsequent time point for which data are available. 
 
10.9 CONTINUED ACCESS  
Data collected from patients enrolled in the Exte nded Investigation (conti nued access) phase will be 
evaluated separately from that of the Primary Inv estigation. No formal hypothesis testing will be 
performed in this separate continued access cohort. On ly descriptive statistics will be presented on this 
cohort.   
 
11. ADMINISTRATIVE PROCEDURES 
11.1 STATEMENT OF COMPLIANCE  
This clinical investigation will follow the internati onal standard for Clinical Investigation of Medical 
Devices for Human Subjects -- Good Clinical Practice (ISO 14155:2011).  The Sponsor and Investigator(s) will comply with their responsibilities as defined in 21 CFR 812.
 
11.2 RESPONSIBILITIES  
1. Sponsor : Endologix is responsible as the Sponsor to en sure proper site and investigator selection, 
availability of signed investigator agreements prio r to study initiation, ava ilability of regulatory and 
EC/IRB approval prior to the initiation of the st udy at any site, obtaining and maintaining 
appropriate insurance policies for the study, and management and monitoring of the study with 
special attention to verification of all clinical requirements, adherence to protocol, good clinical 
practices and compliance with applicable governme nt and institutional regulations. Furthermore, 
the sponsor is responsible for ensuring proper re gulatory approvals are obtained, and reporting to 
regulatory authorities per applicable regulations. 
2. Investigators : Each investigator and study site is requir ed to conduct the clinical investigation in 
accordance with the protocol, the signed investigator agreement, Good Clinical Practices (GCP), 
all applicable laws and regulations and any cond itions or restrictions imposed by the reviewing 
EC/IRB. This includes compliance with requireme nts related to EC/IRB approval and reporting, 
and proper patient informed consent prior to partic ipation in the study. The investigator is also 
responsible for protecting the rights, safety, and welfare of the subjects under his or her care. 
a. Each investigator is responsible for s upervising all procedures conducted under this 
protocol at his or her institution.  
b. Furthermore, the investigator is responsi ble for ensuring that data are completely, 
accurately, and promptly entered in each pa tient’s eCRFs and related documents are 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
63 
 
 
 available to verify the accuracy of the eCRFs,  and for ensuring the clinical monitor has 
access to all necessary records to ensu re the integrity of the data.  
3. CT Scan Core Laboratory : The CT Scan Core Laboratory is a contract supplier having validated 
processes that is responsible for receipt, de-iden tification, handling, processing, and assessment of 
all submitted CT scans preoperatively and postoperativ ely and for reporting of results per a written, 
approved protocol.  
4. Data Management Group : The data management group is responsible for electronic data capture 
database development, validation, control and ma nagement of input from study sites/monitored 
data, maintenance, and reporting for statistical analysis. 
5. Clinical Events Committee : The independent clinical events committee will consist of at least three 
physician members and is responsible for review  of events and complications documented on the 
eCRFs and in source documents by the study PIs du ring the trial, and for categorization of these 
events according to the event defi nitions and primary endpoint cr iteria in this protocol.  An 
independent clinical safety review will ex amine all AEs and SAEs.  MAEs will undergo 
adjudication by the CEC panel. Reviews will oc cur on an ongoing basis throughout the trial as 
events are reported. The adjudicated events will be reviewed by the Data Safety Monitoring Board. 
6. Data Safety Monitoring Board (DSMB) : Consistent with the U.S. FDA guidance document 
Establishment and Operation of Clinical Trial Data Monitoring Committees , Endologix has 
established a DSMB having pertinent expertise to re view on a regular basis adjudicated safety data 
accumulated and trial progress (i.e., enrollment am ong groups; completeness and timeliness of data; 
protocol deviations; etc.) from its ongoing clinical  investigations. The DSMB consists of five 
members, two of which must be physicians with  specialty training in endovascular repair. One 
member of the DSMB is a statistician. The DS MB will be convened to review interim data 
accumulated during the trial and to render a reco mmendation for enrollment in the trial: continue; 
amend; suspend; or, terminate. All action items  discussed during the meeting will be documented 
in the minutes, with agreed upon target completi on dates for resolution. The final meeting minutes 
will be distributed to all DSMB members. Endologix will disclose the recommendations of the 
DSMB to the US FDA in its annual progress reports to the IDE. 
 
7. Independent Reviewer :  The Independent Reviewer will be an expert in endovascular 
therapy for repair of abdominal aortic and aortoiliac aneurysms. The Independent 
Reviewer will review all aneurysm-related images prior to subject enrollment into the 
study. Approval by the Independent Review er will include assessing vascular suitability 
for treatment with the study device and revi ew of anatomic measurements provided by 
the Core Lab to determine each patient’s elig ibility. More than one Independent Reviewer 
may be required for case selection decision adjudication.  
8. Biostatistician : The biostatistician is responsible for th e development and implementation of the 
data analysis plan, for conducting the data an alysis, and for reporting it per the plan.   
11.3 PATIENT PROTECTION  
This clinical investigation will be conducted in acco rdance with the ethical principles that have their 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
64 
 
 
 origin in the Declaration of Helsinki. Written in formed consent, in acco rdance with applicable 
international and local study center regulations, must  be obtained from each patient, or from their legal 
representative, prior to the formal screening process as outlined in this protocol . The PI will retain a 
copy of the signed informed consent document in e ach subject’s record, and provide a copy to the 
subject. The PI will not request the written informed consent of any patient, and will not allow any 
patient to participate in the investig ation before obtaining EC/IRB approval. 
Attachment 2  provides a sample of the consent form that ma y be used for the study. The sample contains 
the minimal consent language content that must be incorporated into the Informed Consent Document. 
Other elements or language may be added, or minor edits to the language may be made, but no 
substantial content may be deleted.  
Prior to starting the study, the PI will provide Endo logix with a copy of the sample Informed Consent 
Document approved by the EC/IRB with document ed evidence that the EC/IRB has approved the 
protocol.   
Appropriate precautions will be ta ken to maintain confidentiality of patient medical records and 
personal information. However, the patient’s name may be disclosed to the sponsor or designee, or any 
health authorities if they inspect the study records. A report of this study may be published; however the patient’s identity will not be disclosed. 
11.4 P
ROTOCOL CHANGES  
The PI should not implement any deviation from or  changes to the protocol without approval by 
Endologix and prior review and documented appr oval from the governing EC/IRB. The only exception 
to this is where necessary to el iminate immediate hazards to study subjects, or when changes involve 
only administrative aspects (e.g., change in  monitors, telephone numbers, etc.). 
A report of withdrawal of EC/ IRB approval must be submitted to the Sponsor within five working 
days. 
11.5 DOCUMENTATION  
Clinical Investigator’s Brochure : Prior to or at the time of training for the study, the PI will be provided 
with a Clinical Investigator’s Brochure (CIB). Th is document serves as a briefing document to provide 
reports of prior investigations regarding nonclinical  and clinical safety and effectiveness studies, as 
well as published and unpublished inform ation for reference and review.  
Source Documents : Source documents may include a patient’s medical record, hospital charts, clinic 
charts, the investigator’s study files, questionnaires,  as well as the results of diagnostic tests such as 
laboratory tests, CT scans, angiograms, and the li ke. Source document worksheets will be provided by 
Endologix for use by study personnel. 
The following information should be included in the patient’s medical record: 
 Patient’s name and contact information; 
 The study title, number/name, and sponsor name; 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
65 
 
 
  The patient ID number; 
 A statement that written informed consent was obtained; 
 Date of procedure and implanted device information; 
 Dates of all visits; 
 Occurrence of complication and adverse even ts, hospitalizations, or adverse events; 
 Date patient exited the study, and a notation as to whether the patient completed the study or 
discontinued, with the corresponding reason. 
Electronic Case Report Form Completion : The PI who signs the protocol signature page must 
personally electronically sign the eCRFs to ensure  that the observations and findings are entered 
correctly and completely. The eCRFs are to be entere d in a timely manner at the intervals specified by 
Endologix and this protocol. 
All eCRFs must be entered as instructed. An explanat ion must be provided for any missing data points. 
Completion instructions and training will be provided to each site for reference. 
All eCRFs will be reviewed and monitored for comp leteness and clarity. Queries for missing or unclear 
data will be made as necessary throughout the stud y. Timely resolution of queries is required by 
institutional staff and the PI. 
Study Logs :  The following logs will be maintained for the study: 
 Investigator and site training to the protocol (Training Log) 
 Authorized study site personnel (Site Signature Log) 
 Patient consent and screening (Enrollment Log) 
 Monitoring visit tracking (Site Visit Log) 
 Nellix Inventory eTracking Log (Device Accountability Log) 
Document Retention : Study-related correspondence, patient record s, consent forms, records of device 
implant, and source documents are to be maintained  by the study site. Endologix requires that it be 
notified in writing if the PI wishes to relinquish owners hip of the data and information so that mutually 
agreed upon arrangements can be made for tran sfer of ownership to a qualified entity. 
Publication : Endologix, as the sponsor of record, has a proprietary interest in this study. Authorship 
and manuscript composition will reflect joint cooperati on between multiple investigators and sites, core 
laboratories, and Endologix. Authorship will be est ablished prior to writing of the manuscript. No 
individual publications will be allowed prior to the co mpletion of the final report for this study and as 
agreed in writing by Endologix.  
11.6 MONITORING PLAN 
Written procedures have been established by Endologix for monitoring clinical investigations, to assure 
the quality of the study and to assure that each pe rson involved in the m onitoring process carries out 
his or her duties. Standardized written procedures, sufficiently detailed to cover the general aspects of 
clinical investigations, will be used as a basi c monitoring plan and will be supplemented by more 
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
66 
 
 
 specific or additional procedures, as required by the clinical investigation. A pre-study monitoring visit 
or meeting (SIV/SAV) will be conducted to ensure that the PI clearly understands and accepts the 
obligations incurred in undertaking the clinical investigation as set forth in relevant international 
standard, and that the facilities are acceptable. Pe riodic monitoring visits will be conducted with 
adequate frequency to ensure that the PI’s obligations are being fulfilled and that the facilities continue 
to be acceptable.  
Site Termination : If the Sponsor or a clinical monitor becomes aware that a PI is not complying with 
the signed Investigator’s Agreement,  the Investigational Plan, the re quirements of applicable health 
authority regulations, or any conditions of appr oval imposed by the reviewing EC/IRB or health 
authority, Endologix will immediatel y either secure compliance or terminate the PI’s participation in 
the study. The final action will be taken with the goal of assuring the rights, safety and welfare of the 
subjects. 
Monitor Name and Address : Monitoring procedures will be performed under the direction of: 
 Shari O’Quinn  
 VP, Clinical & Regulatory Affairs  
 Endologix, Inc.2 Musick, Irvine, CA 92618 
 Tel: (949) 598-4650  
 CRFs, AE reports, source documents as required,  invoices for payments per executed agreements, 
 and all correspondence are to be forwarded to:  
Endologix, Inc.  
Clinical Affairs Department 
2 Musick, Irvine, CA 92618 Tel: (949) 595-7200 
Fax: (949) 595-7373 
  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
67 
 
 
 12. REFERENCES 
1. AbuRahma A, Campbell J, Stone PA, et al. The correlatio n of aortic neck length to early and late outcomes 
in endovascular repair patients. J Vasc Surg 2009;50:738-48. 
2. Arko FA, Filis KA, Seidel SA, et  al. How many patients with infra renal aneurysms are candidates for 
endovascular repair? J Endovasc Ther 2004;11:33-40. 
3. ASTM F1058:2002, Standard Specification for Wrought 40Cobalt-20Chromium-16Iron-15Nickel-
7Molybdenum Alloy Wire and Strip for Surgical Implant Applications (UNS R30003 and UNS R30008). 
4. Browne TF, Hartley D, Purchas S, et al. A fenestrated covered suprarenal aortic stent. Eur J Vasc Endovasc 
Surg 1999;18:445-9. 
5. Carpenter JP, Baum RA, Barker CF, et al. Impact of ex clusion criteria on patient selection for endovascular 
abdominal aortic aneurysm repair. J Vasc Surg 2001;34:1050-4. 
6. Fleiss, J.  The statistical basis of  meta-analysis. Statistical Methods in Medical Research 1993;2: 121-45. 
7. Friedman L, Furberg C, and DeMets D.  Fundamental s of Clinical Trials. 1985: Mosby Year Book, St. 
Louis. 
8. Fulton JJ, Farber MA, Marston WA, et al. Endovascula r stent-graft repair of pararenal and type IV 
thoracoabdominal aortic aneurysms with adjunctive visc eral reconstruction. J Vasc Surg 2005;41:191-8. 
9. Harrell F, Lee K, and Mark D. Mu ltivariable prognostic models: issues in developing models, evaluating 
assumptions, and adequacy, and measuring and reducing errors. Statistics in Medicine 1996;15:361-87 
10. Hoyert DL, Arias E, Smith B L, et al. Deaths: final data for 1999. Natl Vital Stat Rep 2001; 49(8):1-113. 
11. Jeyabalan G, Park T, Rhee RY, et al. Comparison of modern open infrarenal and pararenal abdominal 
aortic aneurysm repair on early outcomes and renal dysfunction at one year. J Vasc Surg 2011;54:654-9. 
12. ISO 14155:2011, Clinical Investigations of Medical Devices for Human Patients: Good Clinical Practice 
13. Leurs LJ, Kievit J, Dagnelie PC, et al. Influence of infrarenal neck length on outcome of endovascular 
abdominal aortic aneurysm repair. J Endovasc Ther 2006;13:640–8. 
14. Meinert C. Clinical Trials: Design, Conduct, and An alysis. 1986; Oxford University Press. New York, NY   
15. Park JH, Chung JW, Cho IW, et al. Fenestrated stent graf ts for preserving visceral brnaches in the treatment 
of abdominal aortic aneurysms: preliminary results . J Vasc Interventional Radiology 1996;7:819-23. 
16. Pocock S. Clinical Trials (A Practical Appr oach). 1983: John Wiley and Sons, Chichester. 
17. Rubin D. Multiple Imputation for Nonresponse in Surveys. 1987: John Wiley and Sons, New York. 
18. Turnbull I, Criado FJ, Sanchez L, et al. Five year results for the Talent enhanced low profile system 
abdominal stent graft pivotal trial including early an d long term safety and efficacy. J Vasc Surg 2010; 
51:537-44. 
19. U.S. Department of Health and Human Services, Guid ance For Industry. E9 Statistical Principles for 
Clinical Trials, September 1998. 
20. U.S. Department of Health and Human Services, Guid ance For Industry. ICH E6, Good Clinical Practice: 
Consolidated Guidance, April 1996. 
  
Endologix, Inc.   April 2018 
Protocol CP-0008 Rev.11.6  
Nellix IDE Study, EVAS I with Continued Access 
 
Confidential . This document and the information c ontained herein may not be reproduced, used or disclosed without written 
permission from Endologix, Inc. 
68 
 
 
  
13. APPENDIX A: LIST OF COILS INVESTIGATORS MAY USE ADJUNCTIVELY 
WITH ONYX®  
Coil Name Manufacturer 
Interlock Boston Scientific 
Nester Cook Medical 
Concerto Medtronic 
POD Penumbra 
Ruby Penumbra 
Azur Terumo 
 
 